score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.2295	122.0	0.0	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.V600E (Missense)	1	HNSC_MUSE	TCGA-UF-A7JV-01A-11D-A34J-08	TCGA-UF-A7JV-10A-01D-A34M-08
Putatively Actionable	FDA-Approved		Guideline	Somatic Variant	IDH2	Missense	p.R140Q	0.2766	94.0	0.0	0.0		Putatively Actionable	Enasidenib	IDH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted regular approval to enasidenib for the treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.	Celgene Corporation. Idhifa (enasidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf. Revised September 2019. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209606s002lbl.pdf								Putatively Actionable	0	More frequent in Acute Myeloid Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					IDH2 p.R140Q (Missense)		HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.2766	47.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		HNSC_MUSE	TCGA-P3-A5QF-01A-11D-A28R-08	TCGA-P3-A5QF-10A-01D-A28U-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4516	31.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		HNSC_MUSE	TCGA-BA-A4IH-01A-11D-A25Y-08	TCGA-BA-A4IH-10A-01D-A25Y-08
Putatively Actionable	FDA-Approved			Somatic Variant	FGFR3	Missense	p.S249C	0.4255	47.0	0.0	0.0		Putatively Actionable	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.S249C (Missense)		HNSC_MUSE	TCGA-CN-A6V7-01A-12D-A34J-08	TCGA-CN-A6V7-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1376	109.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-UF-A7J9-01A-12D-A34J-08	TCGA-UF-A7J9-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.55	60.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-BA-A4IF-01A-11D-A25Y-08	TCGA-BA-A4IF-10A-01D-A25Y-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047L	0.3511	131.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047L (Missense)	1	HNSC_MUSE	TCGA-BA-5149-01A-01D-1512-08	TCGA-BA-5149-10A-01D-1512-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2364	110.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2917	72.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-IQ-A61E-01A-22D-A30E-08	TCGA-IQ-A61E-10A-01D-A30H-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.3171	82.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-CV-7422-01A-21D-2078-08	TCGA-CV-7422-10A-01D-2078-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.4531	64.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-CN-6024-01A-11D-1683-08	TCGA-CN-6024-10A-01D-1683-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2149	121.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CV-5442-01A-01D-1512-08	TCGA-CV-5442-11A-01D-1512-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2823	124.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-BB-4223-01A-01D-1434-08	TCGA-BB-4223-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.6237	93.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-P3-A5QF-01A-11D-A28R-08	TCGA-P3-A5QF-10A-01D-A28U-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2289	83.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-H7-7774-01A-21D-2078-08	TCGA-H7-7774-10A-01D-2078-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1538	208.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.23	100.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2449	49.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-CV-A45V-01A-21D-A25D-08	TCGA-CV-A45V-10A-01D-A25E-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.6337	101.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CQ-A4CG-01A-11D-A25Y-08	TCGA-CQ-A4CG-10A-01D-A25Y-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2475	101.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-F7-8489-01A-31D-2394-08	TCGA-F7-8489-10A-01D-2394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.6765	238.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-CR-5249-01A-01D-1512-08	TCGA-CR-5249-10A-01D-1512-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.1701	147.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-CN-A498-01A-11D-A24D-08	TCGA-CN-A498-10A-01D-A24F-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.2273	44.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-QK-AA3K-01A-11D-A391-08	TCGA-QK-AA3K-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.2817	71.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.3077	143.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-CR-5243-01A-01D-1512-08	TCGA-CR-5243-10A-01D-1512-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.3273	110.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.1944	72.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-HD-7832-01A-11D-2129-08	TCGA-HD-7832-10A-01D-2129-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2237	76.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-HD-7754-01A-11D-2078-08	TCGA-HD-7754-10A-01D-2078-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.305	141.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-TN-A7HI-01A-11D-A34J-08	TCGA-TN-A7HI-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2245	98.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-UF-A7JV-01A-11D-A34J-08	TCGA-UF-A7JV-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.1089	303.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CN-4741-01A-01D-1434-08	TCGA-CN-4741-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5556	81.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CV-5435-01A-01D-1683-08	TCGA-CV-5435-10A-01D-1870-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3143	105.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-P3-A6T0-01A-12D-A34J-08	TCGA-P3-A6T0-10A-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.6051	195.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-BA-4077-01B-01D-1434-08	TCGA-BA-4077-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.3256	129.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-CN-5373-01A-01D-1434-08	TCGA-CN-5373-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.6753	77.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-CN-6998-01A-23D-2012-08	TCGA-CN-6998-10A-01D-2013-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.48	75.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-CN-6021-01A-11D-1683-08	TCGA-CN-6021-10A-01D-1683-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.128	164.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CN-5365-01A-01D-1434-08	TCGA-CN-5365-10A-01D-1434-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C420R	0.2733	150.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C420R (Missense)	1	HNSC_MUSE	TCGA-BA-A8YP-01A-11D-A391-08	TCGA-BA-A8YP-10A-01D-A394-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E542K	0.2381	126.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E542K (Missense)	1	HNSC_MUSE	TCGA-UF-A71B-01A-12D-A34J-08	TCGA-UF-A71B-10B-01D-A34M-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047R	0.4231	78.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047R (Missense)	1	HNSC_MUSE	TCGA-F7-A61S-01A-11D-A28R-08	TCGA-F7-A61S-10A-01D-A28U-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.3542	240.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CR-6487-01A-11D-1870-08	TCGA-CR-6487-10A-01D-1870-08
Putatively Actionable	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E545K	0.5047	107.0	0.0	0.0		Putatively Actionable	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E545K (Missense)	1	HNSC_MUSE	TCGA-CR-6472-01A-11D-1870-08	TCGA-CR-6472-10A-01D-1870-08
Putatively Actionable	Preclinical			Somatic Variant	MAPK1	Missense	p.E322K	0.4054	74.0	0.0	0.0		Putatively Actionable	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322K (Missense)	0	HNSC_MUSE	TCGA-CV-5442-01A-01D-1512-08	TCGA-CV-5442-11A-01D-1512-08
Putatively Actionable	Preclinical			Somatic Variant	MAPK1	Missense	p.E322K	0.1928	83.0	0.0	0.0		Putatively Actionable	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322K (Missense)	0	HNSC_MUSE	TCGA-CN-A63Y-01A-11D-A30E-08	TCGA-CN-A63Y-10A-01D-A30H-08
Putatively Actionable	Preclinical			Somatic Variant	MAPK1	Missense	p.E322K	0.15	80.0	0.0	0.0		Putatively Actionable	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322K (Missense)	0	HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Putatively Actionable	Preclinical			Somatic Variant	AKT1	Missense	p.E17K	0.3714	35.0	0.0	0.0		Putatively Actionable	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E17K (Missense)	0	HNSC_MUSE	TCGA-CV-5443-01A-01D-1512-08	TCGA-CV-5443-11A-01D-1512-08
Putatively Actionable	Preclinical			Somatic Variant	MAPK1	Missense	p.E322K	0.1739	69.0	0.0	0.0		Putatively Actionable	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322K (Missense)	0	HNSC_MUSE	TCGA-CQ-5334-01A-01D-1683-08	TCGA-CQ-5334-10A-01D-1683-08
Putatively Actionable	Preclinical			Somatic Variant	MAPK1	Missense	p.E322K	0.5727	110.0	0.0	0.0		Putatively Actionable	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322K (Missense)	0	HNSC_MUSE	TCGA-C9-A480-01A-12D-A24D-08	TCGA-C9-A480-10A-01D-A24F-08
Putatively Actionable			Guideline	Somatic Variant	SETBP1	Missense	p.D868Y	0.6389	72.0	0.0	0.0																Putatively Actionable	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D868Y (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.G466E	0.2774	137.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.G466E (Missense)	1	HNSC_MUSE	TCGA-D6-A6EN-01A-11D-A31L-08	TCGA-D6-A6EN-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.P751A	0.041	732.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.P751A (Missense)	1	HNSC_MUSE	TCGA-BB-4223-01A-01D-1434-08	TCGA-BB-4223-10A-01D-1434-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594N	0.1795	78.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.D594N (Missense)	1	HNSC_MUSE	TCGA-CN-A63Y-01A-11D-A30E-08	TCGA-CN-A63Y-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.F388L	0.1118	152.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.F388L (Missense)	1	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L312I	0.234	141.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.L312I (Missense)	1	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.E648Q	0.1915	47.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.E648Q (Missense)	1	HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.F635I	0.1765	102.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.F635I (Missense)	1	HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.Q609E	0.1692	65.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf					BRAF p.Q609E (Missense)	1	HNSC_MUSE	TCGA-BA-5152-01A-02D-1870-08	TCGA-BA-5152-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.L38V	0.3125	112.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.L38V (Missense)	1	HNSC_MUSE	TCGA-CV-7103-01A-21D-2012-08	TCGA-CV-7103-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.D191N	0.0797	953.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.D191N (Missense)	1	HNSC_MUSE	TCGA-BA-6872-01A-11D-1870-08	TCGA-BA-6872-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.F712L	0.2424	66.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.F712L (Missense)	1	HNSC_MUSE	TCGA-CV-7427-01A-11D-2078-08	TCGA-CV-7427-10A-01D-2078-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.S229C	0.3822	157.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.S229C (Missense)	1	HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G588S	0.3718	78.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G588S (Missense)	1	HNSC_MUSE	TCGA-IQ-7630-01A-11D-2078-08	TCGA-IQ-7630-10A-01D-2078-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E967A	0.3684	133.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E967A (Missense)	1	HNSC_MUSE	TCGA-HD-7832-01A-11D-2129-08	TCGA-HD-7832-10A-01D-2129-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.E872G	0.3203	153.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.E872G (Missense)	1	HNSC_MUSE	TCGA-MT-A67A-01A-11D-A30E-08	TCGA-MT-A67A-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.P373Q	0.1951	82.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.P373Q (Missense)	1	HNSC_MUSE	TCGA-CV-6961-01A-21D-1912-08	TCGA-CV-6961-10A-01D-1912-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.I475V	0.2973	74.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.I475V (Missense)	1	HNSC_MUSE	TCGA-CN-4742-01A-02D-1512-08	TCGA-CN-4742-10A-01D-1512-08
Investigate Actionability	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.G503S	0.161	118.0	0.0	0.0		Investigate Actionability	Osimertinib	EGFR inhibition	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf. Revised May 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208065s016lbl.pdf	Investigate Actionability	Gefitinib	EGFR inhibition	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.G503S (Missense)	1	HNSC_MUSE	TCGA-BB-8596-01A-11D-2394-08	TCGA-BB-8596-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.H973R	0.2818	181.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.H973R (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.G812V	0.3929	224.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.G812V (Missense)		HNSC_MUSE	TCGA-BB-7870-01A-11D-2229-08	TCGA-BB-7870-10A-01D-2229-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E767K	0.1913	115.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E767K (Missense)		HNSC_MUSE	TCGA-BA-A6DF-01A-11D-A30E-08	TCGA-BA-A6DF-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.I83M	0.52	25.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.I83M (Missense)		HNSC_MUSE	TCGA-CN-A497-01A-11D-A24D-08	TCGA-CN-A497-10A-01D-A24F-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.N486I	0.3415	82.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.N486I (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.E270K	0.2131	61.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.E270K (Missense)		HNSC_MUSE	TCGA-F7-A50G-01A-11D-A25Y-08	TCGA-F7-A50G-10A-01D-A25Y-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.V111A	0.3051	59.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.V111A (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.R357W	0.1786	140.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					EZH2 p.R357W (Missense)		HNSC_MUSE	TCGA-CV-7252-01A-11D-2012-08	TCGA-CV-7252-10A-01D-2013-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	KIT	Missense	p.R888L	0.2989	87.0	0.0	0.0		Investigate Actionability	Regorafenib	KIT inhibition	Targeted therapy	FDA-approved for locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.	Bayer HealthCare Pharmaceuticals, Inc. Stivarga (regorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf. Revised June 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.R888L (Missense)		HNSC_MUSE	TCGA-QK-A8Z8-01A-11D-A391-08	TCGA-QK-A8Z8-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D762H	0.2	15.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D762H (Missense)		HNSC_MUSE	TCGA-CV-5442-01A-01D-1512-08	TCGA-CV-5442-11A-01D-1512-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.D786N	0.5909	22.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.D786N (Missense)		HNSC_MUSE	TCGA-CV-5442-01A-01D-1512-08	TCGA-CV-5442-11A-01D-1512-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.R669G	0.4	75.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.R669G (Missense)		HNSC_MUSE	TCGA-QK-A6V9-01A-11D-A34J-08	TCGA-QK-A6V9-10B-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	MET	Splice Site	p.X656_splice	0.2193	187.0	0.0	0.0		Investigate Actionability	Capmatinib	MET inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to capmatinib for adult patients with metastatic non-small cell lung cancer whose tumors have a mutation that leads to MET exon 14 skipping as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tabrecta (capmatinib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf. Revised May 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213591s000lbl.pdf																	MET p.X656_splice (Splice Site)		HNSC_MUSE	TCGA-UF-A718-01A-22D-A34J-08	TCGA-UF-A718-10A-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.G380R	0.2105	228.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.G380R (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.P250S	0.4333	30.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.P250S (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.V50I	0.2043	93.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.V50I (Missense)		HNSC_MUSE	TCGA-CV-6941-01A-11D-1912-08	TCGA-CV-6941-10A-01D-1912-08
Investigate Actionability	FDA-Approved			Somatic Variant	FGFR3	Missense	p.A257V	0.0824	85.0	0.0	0.0		Investigate Actionability	Erdafitinib	FGFR inhibition	Targeted therapy	Erdafitinib is indictated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma that has susceptible FGFR3 or FGFR2 genetic alterations, and has progressed during or following at least one line of prior platinum-containing chemotherapy including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.	Janssen Products, LP. Balversa (erdafitinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf																	FGFR3 p.A257V (Missense)		HNSC_MUSE	TCGA-CN-4728-01A-01D-1434-08	TCGA-CN-4728-10A-01D-1434-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R487P	0.2459	122.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R487P (Missense)	0	HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.L350M	0.2209	86.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.L350M (Missense)	0	HNSC_MUSE	TCGA-UF-A71E-01A-31D-A34J-08	TCGA-UF-A71E-10B-01D-A34M-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R764H	0.4872	39.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R764H (Missense)	0	HNSC_MUSE	TCGA-CN-A642-01A-12D-A30E-08	TCGA-CN-A642-10A-01D-A30H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R558C	0.3049	82.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R558C (Missense)	0	HNSC_MUSE	TCGA-CR-6471-01A-11D-1870-08	TCGA-CR-6471-10A-01D-1870-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.V536M	0.2836	134.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.V536M (Missense)	0	HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R690M	0.1154	52.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R690M (Missense)	0	HNSC_MUSE	TCGA-CV-A45Z-01A-21D-A25D-08	TCGA-CV-A45Z-10A-01D-A25E-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.A987E	0.2459	122.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.A987E (Missense)	0	HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.G257S	0.3617	47.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.G257S (Missense)	0	HNSC_MUSE	TCGA-CV-A45Q-01A-11D-A24D-08	TCGA-CV-A45Q-10A-01D-A24F-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Missense	p.R979H	0.2061	131.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R979H (Missense)	0	HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.Q44H	0.3284	67.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.Q44H (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.Y483D	0.3398	103.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.Y483D (Missense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Y2884*	0.2039	103.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Y2884* (Nonsense)		HNSC_MUSE	TCGA-CN-5366-01A-01D-1434-08	TCGA-CN-5366-10A-01D-1434-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.Q2749*	0.3333	111.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.Q2749* (Nonsense)		HNSC_MUSE	TCGA-T2-A6X2-01A-12D-A34J-08	TCGA-T2-A6X2-10B-01D-A34M-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E337V	0.3158	19.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E337V (Missense)		HNSC_MUSE	TCGA-CV-5440-01A-01D-1512-08	TCGA-CV-5440-11A-01D-1512-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.E284Q	0.2667	45.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.E284Q (Missense)		HNSC_MUSE	TCGA-BB-A5HY-01A-11D-A28R-08	TCGA-BB-A5HY-10A-01D-A28U-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.K740N	0.1504	226.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.K740N (Missense)		HNSC_MUSE	TCGA-CV-7433-01A-11D-2129-08	TCGA-CV-7433-10A-01D-2129-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.C585S	0.2708	48.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.C585S (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	BRCA2	Nonsense	p.R2625*	0.2703	111.0	0.0	0.0		Investigate Actionability	Nivolumab + Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Responders were enriched for mutation in BRCA2 mutations, mostly nonsense mutations. 6 of 21 responders had BRCA2 vs. 1 of 17 nonresponders.	Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma Cell. 2016; 165(1):35-44.	https://doi.org/10.1016/j.cell.2016.02.065	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R2625* (Nonsense)		HNSC_MUSE	TCGA-BA-6870-01A-11D-1870-08	TCGA-BA-6870-10A-01D-1870-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.N84S	0.25	36.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.N84S (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A386T	0.4545	44.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A386T (Missense)		HNSC_MUSE	TCGA-CQ-6228-01A-11D-1912-08	TCGA-CQ-6228-10A-01D-1912-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.A373V	0.3158	57.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.A373V (Missense)		HNSC_MUSE	TCGA-HD-7229-01A-11D-2012-08	TCGA-HD-7229-10A-01D-2013-08
Investigate Actionability	Clinical evidence	Clinical evidence		Somatic Variant	RET	Missense	p.T946A	0.4	200.0	0.0	0.0		Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict sensitivity to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137	Investigate Actionability	LOXO-292	RET inhibition	Targeted therapy	Certain missesnse mutations may predict resistance to RET inhibitors	Subbiah V, Velcheti V, Tuch BB, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol. 2018;29(8):1869-1876.	https://doi.org/10.1093/annonc/mdy137										RET p.T946A (Missense)		HNSC_MUSE	TCGA-CR-6472-01A-11D-1870-08	TCGA-CR-6472-10A-01D-1870-08
Investigate Actionability	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.D54Y	0.2517	147.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					NRAS p.D54Y (Missense)	1	HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.R1006C	0.1951	82.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.R1006C (Missense)		HNSC_MUSE	TCGA-CV-7425-01A-11D-2078-08	TCGA-CV-7425-10A-01D-2078-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.T182I	0.2623	61.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.T182I (Missense)		HNSC_MUSE	TCGA-CV-5434-01A-01D-1683-08	TCGA-CV-5434-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.N215S	0.2957	115.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.N215S (Missense)		HNSC_MUSE	TCGA-CQ-7072-01A-21D-A30E-08	TCGA-CQ-7072-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.F219L	0.225	120.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.F219L (Missense)		HNSC_MUSE	TCGA-CV-7099-01A-41D-2012-08	TCGA-CV-7099-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.L50H	0.7	10.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.L50H (Missense)		HNSC_MUSE	TCGA-CV-7253-01A-11D-2012-08	TCGA-CV-7253-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.D313H	0.2973	296.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.D313H (Missense)		HNSC_MUSE	TCGA-P3-A5QF-01A-11D-A28R-08	TCGA-P3-A5QF-10A-01D-A28U-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.I763F	0.2239	67.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.I763F (Missense)		HNSC_MUSE	TCGA-D6-A4Z9-01A-11D-A25D-08	TCGA-D6-A4Z9-10A-01D-A25E-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1202Q	0.2602	123.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1202Q (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.T480A	0.2979	47.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.T480A (Missense)	0	HNSC_MUSE	TCGA-T2-A6X2-01A-12D-A34J-08	TCGA-T2-A6X2-10B-01D-A34M-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.L97Q	0.1371	124.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.L97Q (Missense)		HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.P1234S	0.1444	90.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.P1234S (Missense)		HNSC_MUSE	TCGA-CV-7242-01A-11D-2012-08	TCGA-CV-7242-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.L825F	0.3	190.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.L825F (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Missense	p.P508L	0.2963	27.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.P508L (Missense)	0	HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E1195K	0.2364	55.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E1195K (Missense)		HNSC_MUSE	TCGA-QK-A8ZB-01A-11D-A391-08	TCGA-QK-A8ZB-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.E200D	0.2308	78.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.E200D (Missense)		HNSC_MUSE	TCGA-HD-7753-01A-11D-2078-08	TCGA-HD-7753-10A-01D-2078-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.R1040W	0.1895	153.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.R1040W (Missense)		HNSC_MUSE	TCGA-P3-A5Q5-01A-11D-A28R-08	TCGA-P3-A5Q5-10A-01D-A28U-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S1147F	0.3913	69.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S1147F (Missense)		HNSC_MUSE	TCGA-HD-7832-01A-11D-2129-08	TCGA-HD-7832-10A-01D-2129-08
Investigate Actionability	Clinical evidence			Somatic Variant	TSC2	Nonsense	p.Q404*	0.2258	62.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	TSC2 p.Q404* (Nonsense)		HNSC_MUSE	TCGA-CV-A45Q-01A-11D-A24D-08	TCGA-CV-A45Q-10A-01D-A24F-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.A176D	0.4484	223.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.A176D (Missense)		HNSC_MUSE	TCGA-CV-A6JU-01A-11D-A31L-08	TCGA-CV-A6JU-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.C284Y	0.1439	132.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.C284Y (Missense)		HNSC_MUSE	TCGA-MT-A67D-01A-31D-A30E-08	TCGA-MT-A67D-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.K185E	0.1145	131.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.K185E (Missense)		HNSC_MUSE	TCGA-BA-5556-01A-01D-1512-08	TCGA-BA-5556-10A-01D-1512-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.S467F	0.325	120.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.S467F (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.L633F	0.4783	69.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.L633F (Missense)	0	HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.R921*	0.2963	27.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R921* (Nonsense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Missense	p.Y719C	0.3163	98.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.Y719C (Missense)	0	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.S310F	0.337	273.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.S310F (Missense)		HNSC_MUSE	TCGA-D6-A74Q-01A-11D-A34J-08	TCGA-D6-A74Q-10A-02D-A34M-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB3	Missense	p.G420A	0.225	40.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB3 p.G420A (Missense)		HNSC_MUSE	TCGA-CQ-5334-01A-01D-1683-08	TCGA-CQ-5334-10A-01D-1683-08
Investigate Actionability	Clinical evidence			Somatic Variant	GATA3	Missense	p.S142L	0.2242	165.0	0.0	0.0		Investigate Actionability	Letrozole	Aromatase inhibition	Targeted therapy	GATA3 mutation did not influence baseline Ki67 levels but was enriched in samples exhibiting greater percentage of Ki67 decline. While this requires further validation, it suggests that GATA3 mutation may be a positive marker for aromatase inhibitor response.	Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353-60.	https://doi.org/10.1038/nature11143																	GATA3 p.S142L (Missense)		HNSC_MUSE	TCGA-H7-A6C4-01A-11D-A30E-08	TCGA-H7-A6C4-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Nonsense	p.E356*	0.2849	344.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E356* (Nonsense)		HNSC_MUSE	TCGA-CQ-5326-01A-01D-1870-08	TCGA-CQ-5326-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERBB2	Missense	p.V988I	0.1233	73.0	0.0	0.0		Investigate Actionability	Neratinib	ER signaling inhibition	Targeted therapy	Missesnse mutations may predict sensitivity to HER2 inhibitors	Hyman DM, Piha-Paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers Nature. 2018; 554(7691):189-194.	https://doi.org/10.1038/nature25475																	ERBB2 p.V988I (Missense)		HNSC_MUSE	TCGA-IQ-A61G-01A-11D-A30E-08	TCGA-IQ-A61G-10A-01D-A30H-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R335*	0.7524	105.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R335* (Nonsense)	1	HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q97*	0.2946	112.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q97* (Nonsense)	1	HNSC_MUSE	TCGA-CV-7238-01A-11D-2012-08	TCGA-CV-7238-10A-01D-2013-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.Q171*	0.3846	208.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.Q171* (Nonsense)	1	HNSC_MUSE	TCGA-BA-4074-01A-01D-1434-08	TCGA-BA-4074-10A-01D-1434-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.S229*	0.0872	149.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.S229* (Nonsense)	1	HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Splice Site	p.X27_splice	0.5	34.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.X27_splice (Splice Site)	1	HNSC_MUSE	TCGA-D6-A6ES-01A-12D-A31L-08	TCGA-D6-A6ES-10A-01D-A31J-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Nonsense	p.R130*	0.4742	97.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130* (Nonsense)	1	HNSC_MUSE	TCGA-T2-A6X0-01A-11D-A34J-08	TCGA-T2-A6X0-10B-01D-A34M-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.H821D	0.4	55.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.H821D (Missense)	1	HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.G863C	0.2727	77.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.G863C (Missense)	1	HNSC_MUSE	TCGA-CR-7371-01A-11D-2012-08	TCGA-CR-7371-10A-01D-2013-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.G294R	0.1927	109.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.G294R (Missense)	0	HNSC_MUSE	TCGA-CR-7374-01A-11D-2012-08	TCGA-CR-7374-10A-01D-2013-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.K57N	0.1448	366.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.K57N (Missense)	0	HNSC_MUSE	TCGA-BA-5151-01A-01D-1434-08	TCGA-BA-5151-10A-01D-1434-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.L313F	0.1953	128.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.L313F (Missense)	0	HNSC_MUSE	TCGA-HD-A6I0-01A-11D-A31L-08	TCGA-HD-A6I0-10A-01D-A31J-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.N734D	0.2815	238.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.N734D (Missense)	1	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.R243M	0.156	141.0	0.0	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14										FLT3 p.R243M (Missense)	1	HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	MAP2K1	Missense	p.P323A	0.2347	98.0	0.0	0.0		Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Cell line NCI-H1437 harbors MAP2K1 p.Q56P, a known transformation-component allele of MEK1 originally identified in rat fibroblasts, and is sensitive to treatment with Selumetinib (AZD6244).	Marks JL, Gong Y, Chitale D, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 2008;68(14):5524-8.	https://doi.org/10.1158/0008-5472.CAN-08-0099	Investigate Actionability	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest resistance to Selumetinib.	Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA. 2009;106(48):20411-6.	https://doi.org/10.1073/pnas.0905833106										MAP2K1 p.P323A (Missense)	0	HNSC_MUSE	TCGA-BA-5152-01A-02D-1870-08	TCGA-BA-5152-10A-01D-1870-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.L216V	0.1538	78.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L216V (Missense)		HNSC_MUSE	TCGA-IQ-A61E-01A-22D-A30E-08	TCGA-IQ-A61E-10A-01D-A30H-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Q594K	0.3385	65.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Q594K (Missense)		HNSC_MUSE	TCGA-CV-5441-01A-01D-1512-08	TCGA-CV-5441-11A-01D-1512-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.Q1177H	0.32	50.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Q1177H (Missense)		HNSC_MUSE	TCGA-CR-7373-01A-11D-2012-08	TCGA-CR-7373-10A-01D-2013-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.L227F	0.1008	119.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L227F (Missense)		HNSC_MUSE	TCGA-BA-A4IG-01A-11D-A25Y-08	TCGA-BA-A4IG-10A-01D-A25Y-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.D781N	0.2027	74.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.D781N (Missense)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R401L	0.1683	101.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R401L (Missense)		HNSC_MUSE	TCGA-UF-A7JD-01A-11D-A34J-08	TCGA-UF-A7JD-10A-01D-A34M-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.R1214H	0.1897	58.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.R1214H (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.V811L	0.3627	102.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.V811L (Missense)		HNSC_MUSE	TCGA-CX-7082-01A-11D-2012-08	TCGA-CX-7082-10A-01D-2013-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.L560F	0.4	90.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.L560F (Missense)		HNSC_MUSE	TCGA-IQ-A61G-01A-11D-A30E-08	TCGA-IQ-A61G-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1040I	0.2424	99.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1040I (Missense)	1	HNSC_MUSE	TCGA-CV-A460-01A-21D-A25D-08	TCGA-CV-A460-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q75E	0.1818	231.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q75E (Missense)	1	HNSC_MUSE	TCGA-CV-7424-01A-11D-2078-08	TCGA-CV-7424-10A-01D-2078-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R519G	0.2985	67.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R519G (Missense)	1	HNSC_MUSE	TCGA-CV-A6JM-01A-11D-A31L-08	TCGA-CV-A6JM-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C905S	0.2538	331.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C905S (Missense)	1	HNSC_MUSE	TCGA-UF-A7JO-01A-11D-A34J-08	TCGA-UF-A7JO-10A-01D-A34M-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C604R	0.2754	69.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C604R (Missense)	1	HNSC_MUSE	TCGA-CV-7438-01A-21D-2129-08	TCGA-CV-7438-10A-01D-2129-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R335G	0.1128	390.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R335G (Missense)	1	HNSC_MUSE	TCGA-CR-7374-01A-11D-2012-08	TCGA-CR-7374-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.2105	38.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	HNSC_MUSE	TCGA-CR-7394-01A-11D-2012-08	TCGA-CR-7394-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.1839	87.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	HNSC_MUSE	TCGA-CR-6471-01A-11D-1870-08	TCGA-CR-6471-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1043V	0.2222	63.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1043V (Missense)	1	HNSC_MUSE	TCGA-CR-6471-01A-11D-1870-08	TCGA-CR-6471-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E726K	0.163	92.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E726K (Missense)	1	HNSC_MUSE	TCGA-BA-A6DF-01A-11D-A30E-08	TCGA-BA-A6DF-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.V344G	0.1639	61.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.V344G (Missense)	1	HNSC_MUSE	TCGA-CR-7401-01A-11D-2012-08	TCGA-CR-7401-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G363A	0.2138	276.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G363A (Missense)	1	HNSC_MUSE	TCGA-CN-4739-01A-02D-1512-08	TCGA-CN-4739-10A-01D-1512-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K111N	0.1698	53.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K111N (Missense)	1	HNSC_MUSE	TCGA-CV-6956-01A-21D-2012-08	TCGA-CV-6956-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.P104L	0.3158	76.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.P104L (Missense)	1	HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Y606C	0.2308	52.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Y606C (Missense)	1	HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.Q546R	0.4474	38.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.Q546R (Missense)	1	HNSC_MUSE	TCGA-CV-A45R-01A-11D-A24D-08	TCGA-CV-A45R-10A-01D-A24F-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E970K	0.3645	107.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E970K (Missense)	1	HNSC_MUSE	TCGA-CV-6945-01A-11D-1912-08	TCGA-CV-6945-10A-01D-1912-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.R88Q	0.2968	155.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.R88Q (Missense)	1	HNSC_MUSE	TCGA-P3-A5Q5-01A-11D-A28R-08	TCGA-P3-A5Q5-10A-01D-A28U-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.M1043V	0.211	109.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.M1043V (Missense)	1	HNSC_MUSE	TCGA-CQ-A4C6-01A-11D-A25D-08	TCGA-CQ-A4C6-10A-01D-A25E-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E365V	0.2564	195.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E365V (Missense)	1	HNSC_MUSE	TCGA-CV-7261-01A-11D-2012-08	TCGA-CV-7261-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G451R	0.1121	116.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G451R (Missense)	1	HNSC_MUSE	TCGA-DQ-5630-01A-01D-1870-08	TCGA-DQ-5630-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C901F	0.0857	210.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C901F (Missense)	1	HNSC_MUSE	TCGA-D6-6824-01A-11D-1912-08	TCGA-D6-6824-10A-01D-1912-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E453K	0.2	90.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E453K (Missense)	1	HNSC_MUSE	TCGA-CV-7411-01A-11D-2078-08	TCGA-CV-7411-10A-01D-2078-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.E418K	0.1343	134.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.E418K (Missense)	1	HNSC_MUSE	TCGA-BA-A8YP-01A-11D-A391-08	TCGA-BA-A8YP-10A-01D-A394-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.N345K	0.1969	127.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.N345K (Missense)	1	HNSC_MUSE	TCGA-CV-A6JO-01B-11D-A34J-08	TCGA-CV-A6JO-10A-01D-A34M-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.W328S	0.0761	381.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.W328S (Missense)	1	HNSC_MUSE	TCGA-CX-7082-01A-11D-2012-08	TCGA-CX-7082-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.C971R	0.1566	166.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.C971R (Missense)	1	HNSC_MUSE	TCGA-CN-5360-01A-01D-1434-08	TCGA-CN-5360-10A-01D-1434-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.G1007R	0.3077	65.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.G1007R (Missense)	1	HNSC_MUSE	TCGA-CV-6960-01A-41D-2012-08	TCGA-CV-6960-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.K111E	0.25	104.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.K111E (Missense)	1	HNSC_MUSE	TCGA-CV-6436-01A-11D-1683-08	TCGA-CV-6436-11A-01D-1683-08
Investigate Actionability	Preclinical		Clinical trial	Somatic Variant	PIK3CA	Missense	p.H1047Q	0.4384	146.0	0.0	0.0		Investigate Actionability	Pictilisib	PI3K/AKT/mTOR inhibition	Targeted therapy	In vivo models harboring PIK3CA variants were especially sensitive to GDC-0941.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828								Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PIK3CA p.H1047Q (Missense)	1	HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q780*	0.2524	103.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q780* (Nonsense)		HNSC_MUSE	TCGA-CV-7429-01A-11D-2129-08	TCGA-CV-7429-10A-01D-2129-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q1947*	0.2039	103.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q1947* (Nonsense)		HNSC_MUSE	TCGA-CV-7422-01A-21D-2078-08	TCGA-CV-7422-10A-01D-2078-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.Q207L	0.2812	224.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.Q207L (Missense)		HNSC_MUSE	TCGA-CN-4739-01A-02D-1512-08	TCGA-CN-4739-10A-01D-1512-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.S1316*	0.4747	99.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.S1316* (Nonsense)		HNSC_MUSE	TCGA-CV-7440-01A-11D-2129-08	TCGA-CV-7440-10A-01D-2129-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E957A	0.25	72.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E957A (Missense)		HNSC_MUSE	TCGA-BA-A4IG-01A-11D-A25Y-08	TCGA-BA-A4IG-10A-01D-A25Y-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E858Q	0.1081	185.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E858Q (Missense)		HNSC_MUSE	TCGA-CN-5358-01A-01D-1512-08	TCGA-CN-5358-10A-01D-1512-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.R879H	0.0957	94.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.R879H (Missense)		HNSC_MUSE	TCGA-D6-6515-01A-21D-1870-08	TCGA-D6-6515-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.R1461*	0.6731	52.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1461* (Nonsense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.S294L	0.3333	141.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.S294L (Missense)		HNSC_MUSE	TCGA-P3-A5QE-01A-11D-A28R-08	TCGA-P3-A5QE-10A-01D-A28U-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Nonsense	p.Q528*	0.0552	308.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q528* (Nonsense)		HNSC_MUSE	TCGA-CN-A6V1-01A-12D-A34J-08	TCGA-CN-A6V1-10B-01D-A34M-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Missense	p.E37K	0.09	100.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.E37K (Missense)		HNSC_MUSE	TCGA-CN-A6V1-01A-12D-A34J-08	TCGA-CN-A6V1-10B-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Nonsense	p.E1310*	0.3289	76.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1310* (Nonsense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.D520H	0.6875	160.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.D520H (Missense)		HNSC_MUSE	TCGA-CQ-5332-01A-01D-1683-08	TCGA-CQ-5332-10A-01D-1683-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465G	0.1837	147.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465G (Missense)		HNSC_MUSE	TCGA-QK-A6II-01A-11D-A31L-08	TCGA-QK-A6II-10A-01D-A31J-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.A502V	0.4519	104.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.A502V (Missense)		HNSC_MUSE	TCGA-BA-6868-01B-12D-1912-08	TCGA-BA-6868-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D545H	0.4286	168.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D545H (Missense)	0	HNSC_MUSE	TCGA-BA-6868-01B-12D-1912-08	TCGA-BA-6868-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.V525E	0.5244	82.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.V525E (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I238V	0.301	103.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I238V (Missense)	1	HNSC_MUSE	TCGA-CN-6024-01A-11D-1683-08	TCGA-CN-6024-10A-01D-1683-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I1035V	0.2667	45.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I1035V (Missense)	1	HNSC_MUSE	TCGA-CN-6024-01A-11D-1683-08	TCGA-CN-6024-10A-01D-1683-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T2754A	0.2292	48.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T2754A (Missense)	1	HNSC_MUSE	TCGA-CV-A463-01A-11D-A25Y-08	TCGA-CV-A463-10A-01D-A25Y-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R35C	0.35	140.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R35C (Missense)		HNSC_MUSE	TCGA-CV-7095-01A-21D-2012-08	TCGA-CV-7095-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.192	125.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		HNSC_MUSE	TCGA-UF-A7JO-01A-11D-A34J-08	TCGA-UF-A7JO-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R543G	0.3779	172.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R543G (Missense)		HNSC_MUSE	TCGA-CQ-A4CE-01A-11D-A25Y-08	TCGA-CQ-A4CE-10A-01D-A25Y-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.I2899M	0.4211	228.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.I2899M (Missense)	1	HNSC_MUSE	TCGA-CN-5364-01A-01D-1434-08	TCGA-CN-5364-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R543G	0.1847	222.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R543G (Missense)		HNSC_MUSE	TCGA-CN-5366-01A-01D-1434-08	TCGA-CN-5366-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479L	0.6328	128.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479L (Missense)		HNSC_MUSE	TCGA-BB-7870-01A-11D-2229-08	TCGA-BB-7870-10A-01D-2229-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.4435	248.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		HNSC_MUSE	TCGA-BB-4228-01A-01D-1434-08	TCGA-BB-4228-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.I255V	0.2576	66.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.I255V (Missense)	0	HNSC_MUSE	TCGA-CQ-6222-01A-11D-1912-08	TCGA-CQ-6222-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.S516N	0.1645	152.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S516N (Missense)		HNSC_MUSE	TCGA-CQ-6221-01A-11D-2078-08	TCGA-CQ-6221-10A-01D-2078-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.3571	84.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		HNSC_MUSE	TCGA-CQ-A4CG-01A-11D-A25Y-08	TCGA-CQ-A4CG-10A-01D-A25Y-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R465C	0.1594	207.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R465C (Missense)		HNSC_MUSE	TCGA-BA-A6DF-01A-11D-A30E-08	TCGA-BA-A6DF-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R479Q	0.2545	55.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479Q (Missense)		HNSC_MUSE	TCGA-CQ-5327-01A-01D-1683-08	TCGA-CQ-5327-10A-01D-1683-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.T2333I	0.3421	38.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.T2333I (Missense)	1	HNSC_MUSE	TCGA-HD-A4C1-01A-11D-A24D-08	TCGA-HD-A4C1-10A-02D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.G423A	0.0807	161.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.G423A (Missense)		HNSC_MUSE	TCGA-CV-A45W-01A-11D-A25D-08	TCGA-CV-A45W-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.7671	73.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		HNSC_MUSE	TCGA-CV-6948-01A-11D-1912-08	TCGA-CV-6948-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.S403G	0.1351	74.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.S403G (Missense)	0	HNSC_MUSE	TCGA-CR-7367-01A-11D-2012-08	TCGA-CR-7367-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.K2749N	0.5357	28.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.K2749N (Missense)	1	HNSC_MUSE	TCGA-CV-6950-01A-11D-1912-08	TCGA-CV-6950-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.R343M	0.1563	371.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.R343M (Missense)	0	HNSC_MUSE	TCGA-BA-4074-01A-01D-1434-08	TCGA-BA-4074-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Missense	p.E81K	0.2276	145.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E81K (Missense)	0	HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	AKT1	Missense	p.E49K	0.5	30.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT1 p.E49K (Missense)	0	HNSC_MUSE	TCGA-CV-6936-01A-11D-1912-08	TCGA-CV-6936-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D2997N	0.4068	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D2997N (Missense)	1	HNSC_MUSE	TCGA-CX-7219-01A-11D-2012-08	TCGA-CX-7219-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.F384I	0.381	42.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.F384I (Missense)	0	HNSC_MUSE	TCGA-BB-8601-01A-11D-2394-08	TCGA-BB-8601-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.M145K	0.5789	38.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.M145K (Missense)	0	HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.R337C	0.7917	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.R337C (Missense)	1	HNSC_MUSE	TCGA-CR-7380-01A-11D-2012-08	TCGA-CR-7380-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.Y545C	0.4519	104.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.Y545C (Missense)		HNSC_MUSE	TCGA-CV-A45R-01A-11D-A24D-08	TCGA-CV-A45R-10A-01D-A24F-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.D967H	0.1777	197.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.D967H (Missense)	0	HNSC_MUSE	TCGA-HD-8635-01A-11D-2394-08	TCGA-HD-8635-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Splice Site	p.X1391_splice	0.307	114.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.X1391_splice (Splice Site)		HNSC_MUSE	TCGA-QK-AA3J-01A-11D-A391-08	TCGA-QK-AA3J-10A-01D-A394-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2238Q	0.1143	105.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2238Q (Missense)	1	HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.K152R	0.197	66.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.K152R (Missense)	0	HNSC_MUSE	TCGA-P3-A6T0-01A-12D-A34J-08	TCGA-P3-A6T0-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.D1053N	0.2364	110.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.D1053N (Missense)	1	HNSC_MUSE	TCGA-CN-5373-01A-01D-1434-08	TCGA-CN-5373-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.Y351C	0.1279	86.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.Y351C (Missense)	0	HNSC_MUSE	TCGA-CN-6998-01A-23D-2012-08	TCGA-CN-6998-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505L	0.5507	69.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505L (Missense)		HNSC_MUSE	TCGA-CR-7398-01A-11D-2012-08	TCGA-CR-7398-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.R90Q	0.2137	117.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.R90Q (Missense)		HNSC_MUSE	TCGA-CV-5443-01A-01D-1512-08	TCGA-CV-5443-11A-01D-1512-08
Investigate Actionability	Preclinical			Somatic Variant	ATM	Missense	p.E2932K	0.2864	206.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	HCT116 colorectal cancer cell lines are heterozygous for c.3380C>A and sensitive to PARP inhibition following shRNA depletion of ATM. Deletion of p53 enhances sensitivity.	Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib Translational Oncology. 2017; 10(2):190-196.	https://doi.org/10.1016/j.tranon.2017.01.007																	ATM p.E2932K (Missense)	1	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	AKT2	Missense	p.P471S	0.2619	42.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT2 p.P471S (Missense)	0	HNSC_MUSE	TCGA-CV-7252-01A-11D-2012-08	TCGA-CV-7252-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.L406V	0.1538	104.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261																	MPL p.L406V (Missense)		HNSC_MUSE	TCGA-CV-6961-01A-21D-1912-08	TCGA-CV-6961-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	AKT3	Missense	p.S136C	0.1039	77.0	0.0	0.0		Investigate Actionability	MK-2206	PI3K/AKT/mTOR inhibition	Targeted therapy	Activating mutations in AKT may predict sensitivity to direct inhibition or downstream inhibition of the PI3K/mTOR pathway	Davies BR, Guan N, Logie A, et al. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. Mol Cancer Ther. 2015;14(11):2441-51.	https://doi.org/10.1158/1535-7163.MCT-15-0230																	AKT3 p.S136C (Missense)	0	HNSC_MUSE	TCGA-CV-7407-01A-11D-2078-08	TCGA-CV-7407-10A-01D-2078-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.I299V	0.2095	105.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.I299V (Missense)	0	HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Missense	p.Q507L	0.304	329.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.Q507L (Missense)	0	HNSC_MUSE	TCGA-CN-5360-01A-01D-1434-08	TCGA-CN-5360-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.H689Q	0.1492	181.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.H689Q (Missense)	0	HNSC_MUSE	TCGA-KU-A6H8-01A-21D-A34J-08	TCGA-KU-A6H8-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.W526R	0.1667	126.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.W526R (Missense)		HNSC_MUSE	TCGA-CR-7379-01A-11D-2012-08	TCGA-CR-7379-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.2441	127.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		HNSC_MUSE	TCGA-CV-6436-01A-11D-1683-08	TCGA-CV-6436-11A-01D-1683-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Missense	p.R505G	0.8919	74.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R505G (Missense)		HNSC_MUSE	TCGA-CN-A6V7-01A-12D-A34J-08	TCGA-CN-A6V7-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	MET	Missense	p.Y205C	0.4311	167.0	0.0	0.0		Investigate Actionability	SU11274	MET inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to SU11274.	Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7):3021-31.	https://doi.org/10.1158/0008-5472.CAN-08-2881																	MET p.Y205C (Missense)	0	HNSC_MUSE	TCGA-CV-6935-01A-11D-1912-08	TCGA-CV-6935-10A-01D-1912-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R1111Q	0.3083	133.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R1111Q (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.R685W	0.3041	148.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.R685W (Missense)		HNSC_MUSE	TCGA-CV-6940-01A-11D-1912-08	TCGA-CV-6940-10A-01D-1912-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.G744V	0.2	20.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.G744V (Missense)		HNSC_MUSE	TCGA-HD-8224-01A-11D-2394-08	TCGA-HD-8224-10A-01D-2394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R5Q	0.3333	30.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R5Q (Missense)		HNSC_MUSE	TCGA-CR-6484-01A-11D-1870-08	TCGA-CR-6484-10A-01D-1870-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.D389H	0.1316	190.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.D389H (Missense)		HNSC_MUSE	TCGA-CR-5247-01A-01D-2012-08	TCGA-CR-5247-10A-01D-2013-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E2137K	0.1818	33.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E2137K (Missense)		HNSC_MUSE	TCGA-CN-6018-01A-11D-1683-08	TCGA-CN-6018-10A-01D-1683-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E537G	0.3211	109.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E537G (Missense)		HNSC_MUSE	TCGA-CV-6956-01A-21D-2012-08	TCGA-CV-6956-10A-01D-2013-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.G388V	0.2479	121.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.G388V (Missense)		HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Missense	p.R119C	0.3137	102.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLD1 p.R119C (Missense)		HNSC_MUSE	TCGA-QK-A6IF-01A-11D-A31L-08	TCGA-QK-A6IF-10A-01D-A31J-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.E1091D	0.3125	32.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1091D (Missense)		HNSC_MUSE	TCGA-QK-AA3J-01A-11D-A391-08	TCGA-QK-AA3J-10A-01D-A394-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Missense	p.K1804R	0.4906	53.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.K1804R (Missense)		HNSC_MUSE	TCGA-WA-A7GZ-01A-11D-A34J-08	TCGA-WA-A7GZ-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R267P	0.575	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R267P (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.7826	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		HNSC_MUSE	TCGA-CQ-5332-01A-01D-1683-08	TCGA-CQ-5332-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245C	0.3956	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245C (Missense)		HNSC_MUSE	TCGA-UF-A7J9-01A-12D-A34J-08	TCGA-UF-A7J9-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F134V	0.5	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F134V (Missense)		HNSC_MUSE	TCGA-BA-A4IF-01A-11D-A25Y-08	TCGA-BA-A4IF-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2466	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-CR-7397-01A-11D-2012-08	TCGA-CR-7397-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.G199*	0.2727	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G199* (Nonsense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.314	121.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E285*	0.7031	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285* (Nonsense)		HNSC_MUSE	TCGA-QK-A6IG-01A-11D-A31L-08	TCGA-QK-A6IG-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.L201*	0.2316	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L201* (Nonsense)		HNSC_MUSE	TCGA-CN-5359-01A-01D-1434-08	TCGA-CN-5359-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236C	0.5342	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y236C (Missense)		HNSC_MUSE	TCGA-CV-5434-01A-01D-1683-08	TCGA-CV-5434-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.3404	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-CV-5434-01A-01D-1683-08	TCGA-CV-5434-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.8158	114.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		HNSC_MUSE	TCGA-CV-7255-01A-11D-2012-08	TCGA-CV-7255-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.5625	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-CN-A49B-01A-31D-A24D-08	TCGA-CN-A49B-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286V	0.3404	47.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286V (Missense)		HNSC_MUSE	TCGA-F7-7848-01A-11D-2129-08	TCGA-F7-7848-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126S	0.3929	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126S (Missense)		HNSC_MUSE	TCGA-CN-6012-01A-11D-1683-08	TCGA-CN-6012-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.6237	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		HNSC_MUSE	TCGA-CQ-7072-01A-21D-A30E-08	TCGA-CQ-7072-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.4898	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.4528	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.2785	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		HNSC_MUSE	TCGA-D6-A6EM-01A-21D-A31L-08	TCGA-D6-A6EM-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A161T	0.1932	88.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A161T (Missense)		HNSC_MUSE	TCGA-CN-5367-01A-01D-1434-08	TCGA-CN-5367-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158L	0.3978	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158L (Missense)		HNSC_MUSE	TCGA-HD-8634-01A-11D-2394-08	TCGA-HD-8634-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X367_splice	0.4741	116.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X367_splice (Splice Site)		HNSC_MUSE	TCGA-IQ-A61E-01A-22D-A30E-08	TCGA-IQ-A61E-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194P	0.6957	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194P (Missense)		HNSC_MUSE	TCGA-BA-6868-01B-12D-1912-08	TCGA-BA-6868-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.5769	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CV-A45U-01A-12D-A24D-08	TCGA-CV-A45U-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.1842	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CV-A464-01A-11D-A25Y-08	TCGA-CV-A464-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q331H	0.3151	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331H (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249M	0.3881	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249M (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245D	0.2338	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245D (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R342*	0.75	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R342* (Nonsense)		HNSC_MUSE	TCGA-CV-6003-01A-11D-1683-08	TCGA-CV-6003-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195T	0.3929	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195T (Missense)		HNSC_MUSE	TCGA-C9-A47Z-01A-11D-A24D-08	TCGA-C9-A47Z-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q104*	0.2593	81.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q104* (Nonsense)		HNSC_MUSE	TCGA-CV-7422-01A-21D-2078-08	TCGA-CV-7422-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242F	0.4024	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242F (Missense)		HNSC_MUSE	TCGA-CV-7248-01A-11D-2012-08	TCGA-CV-7248-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193L	0.3542	48.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193L (Missense)		HNSC_MUSE	TCGA-BA-6873-01A-11D-1870-08	TCGA-BA-6873-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L265R	0.6667	24.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L265R (Missense)		HNSC_MUSE	TCGA-CN-6024-01A-11D-1683-08	TCGA-CN-6024-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.3793	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CV-A460-01A-21D-A25D-08	TCGA-CV-A460-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280K	0.2581	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280K (Missense)		HNSC_MUSE	TCGA-CV-A463-01A-11D-A25Y-08	TCGA-CV-A463-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280S	0.3939	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280S (Missense)		HNSC_MUSE	TCGA-CV-A6JE-01A-11D-A31L-08	TCGA-CV-A6JE-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.2203	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		HNSC_MUSE	TCGA-CV-7095-01A-21D-2012-08	TCGA-CV-7095-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.2456	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CR-7371-01A-11D-2012-08	TCGA-CR-7371-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H168L	0.1818	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H168L (Missense)		HNSC_MUSE	TCGA-CN-4737-01A-01D-1434-08	TCGA-CN-4737-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E258A	0.3061	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258A (Missense)		HNSC_MUSE	TCGA-CV-7254-01A-11D-2012-08	TCGA-CV-7254-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173G	0.4933	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173G (Missense)		HNSC_MUSE	TCGA-D6-6826-01A-11D-1912-08	TCGA-D6-6826-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.K305*	0.5195	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K305* (Nonsense)		HNSC_MUSE	TCGA-CQ-A4C7-01A-11D-A25D-08	TCGA-CQ-A4C7-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.4051	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		HNSC_MUSE	TCGA-CV-7424-01A-11D-2078-08	TCGA-CV-7424-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245V	0.449	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245V (Missense)		HNSC_MUSE	TCGA-CR-6474-01A-11D-1870-08	TCGA-CR-6474-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193L	0.3836	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193L (Missense)		HNSC_MUSE	TCGA-CV-A6JM-01A-11D-A31L-08	TCGA-CV-A6JM-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S106R	0.1927	109.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S106R (Missense)		HNSC_MUSE	TCGA-UF-A7JO-01A-11D-A34J-08	TCGA-UF-A7JO-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.6207	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-P3-A5Q6-01A-11D-A28R-08	TCGA-P3-A5Q6-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.3308	130.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		HNSC_MUSE	TCGA-P3-A6T3-01A-11D-A34J-08	TCGA-P3-A6T3-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.3482	112.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		HNSC_MUSE	TCGA-P3-A6T3-01A-11D-A34J-08	TCGA-P3-A6T3-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.1828	93.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-CQ-6224-01A-11D-1912-08	TCGA-CQ-6224-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.3571	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		HNSC_MUSE	TCGA-CQ-A4CE-01A-11D-A25Y-08	TCGA-CQ-A4CE-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I195F	0.3421	114.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I195F (Missense)		HNSC_MUSE	TCGA-UF-A719-01A-12D-A34J-08	TCGA-UF-A719-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278S	0.2727	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278S (Missense)		HNSC_MUSE	TCGA-CN-6011-01A-11D-1683-08	TCGA-CN-6011-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y234C	0.1899	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y234C (Missense)		HNSC_MUSE	TCGA-CV-A6JT-01A-11D-A31L-08	TCGA-CV-A6JT-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163C	0.1776	107.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163C (Missense)		HNSC_MUSE	TCGA-CQ-7064-01A-11D-2394-08	TCGA-CQ-7064-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.6562	224.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		HNSC_MUSE	TCGA-BA-4075-01A-01D-1434-08	TCGA-BA-4075-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.4848	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		HNSC_MUSE	TCGA-BA-A6DA-01A-31D-A31L-08	TCGA-BA-A6DA-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.5873	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-BA-6872-01A-11D-1870-08	TCGA-BA-6872-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141F	0.3913	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141F (Missense)		HNSC_MUSE	TCGA-CV-A6JD-01A-11D-A31L-08	TCGA-CV-A6JD-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T125M	0.2077	130.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T125M (Missense)		HNSC_MUSE	TCGA-CV-A6JD-01A-11D-A31L-08	TCGA-CV-A6JD-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.3784	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		HNSC_MUSE	TCGA-CV-7099-01A-41D-2012-08	TCGA-CV-7099-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337C	0.6818	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337C (Missense)		HNSC_MUSE	TCGA-HD-8224-01A-11D-2394-08	TCGA-HD-8224-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.2453	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CN-5364-01A-01D-1434-08	TCGA-CN-5364-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271V	0.6429	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271V (Missense)		HNSC_MUSE	TCGA-CV-7253-01A-11D-2012-08	TCGA-CV-7253-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R280G	0.5938	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R280G (Missense)		HNSC_MUSE	TCGA-CQ-6220-01A-11D-1912-08	TCGA-CQ-6220-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.4935	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		HNSC_MUSE	TCGA-CN-A63T-01A-11D-A28R-08	TCGA-CN-A63T-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275Y	0.4286	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275Y (Missense)		HNSC_MUSE	TCGA-F7-A50I-01A-11D-A28R-08	TCGA-F7-A50I-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D281Y	0.5833	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D281Y (Missense)		HNSC_MUSE	TCGA-CN-A641-01A-11D-A30E-08	TCGA-CN-A641-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L348S	0.1897	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L348S (Missense)		HNSC_MUSE	TCGA-HD-A633-01A-11D-A28R-08	TCGA-HD-A633-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S127Y	0.4151	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S127Y (Missense)		HNSC_MUSE	TCGA-CR-6493-01A-11D-1870-08	TCGA-CR-6493-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.6875	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		HNSC_MUSE	TCGA-CV-7418-01A-11D-2078-08	TCGA-CV-7418-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.3516	128.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173M (Missense)		HNSC_MUSE	TCGA-CN-5366-01A-01D-1434-08	TCGA-CN-5366-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.5172	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-CV-7438-01A-21D-2129-08	TCGA-CV-7438-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C141Y	0.5814	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C141Y (Missense)		HNSC_MUSE	TCGA-QK-A6IH-01A-11D-A31L-08	TCGA-QK-A6IH-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.473	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CN-5356-01A-01D-1434-08	TCGA-CN-5356-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163C	0.541	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163C (Missense)		HNSC_MUSE	TCGA-D6-A4Z9-01A-11D-A25D-08	TCGA-D6-A4Z9-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R267G	0.5484	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R267G (Missense)		HNSC_MUSE	TCGA-CR-7373-01A-11D-2012-08	TCGA-CR-7373-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179L	0.449	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179L (Missense)		HNSC_MUSE	TCGA-CQ-A4C9-01A-11D-A25D-08	TCGA-CQ-A4C9-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3551	107.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-IQ-A61L-01A-11D-A30E-08	TCGA-IQ-A61L-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.213	108.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-IQ-A61L-01A-11D-A30E-08	TCGA-IQ-A61L-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V218G	0.2414	29.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V218G (Missense)		HNSC_MUSE	TCGA-CQ-A4CB-01A-11D-A25D-08	TCGA-CQ-A4CB-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242F	0.4259	108.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242F (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.7037	27.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		HNSC_MUSE	TCGA-CQ-6221-01A-11D-2078-08	TCGA-CQ-6221-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.8824	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-CV-5973-01A-11D-1683-08	TCGA-CV-5973-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E286*	0.5	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286* (Nonsense)		HNSC_MUSE	TCGA-CX-A4AQ-01A-11D-A25D-08	TCGA-CX-A4AQ-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y205C	0.4038	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205C (Missense)		HNSC_MUSE	TCGA-CV-6934-01A-11D-1912-08	TCGA-CV-6934-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163C	0.2195	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163C (Missense)		HNSC_MUSE	TCGA-CV-7089-01A-11D-2012-08	TCGA-CV-7089-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.2577	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		HNSC_MUSE	TCGA-CN-4729-01A-01D-1434-08	TCGA-CN-4729-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.24	100.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		HNSC_MUSE	TCGA-CN-4729-01A-01D-1434-08	TCGA-CN-4729-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E339*	0.2941	17.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E339* (Nonsense)		HNSC_MUSE	TCGA-CV-7423-01A-11D-2078-08	TCGA-CV-7423-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179P	0.2951	61.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179P (Missense)		HNSC_MUSE	TCGA-CQ-7065-01A-11D-2078-08	TCGA-CQ-7065-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.6023	176.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CN-4727-01A-01D-1434-08	TCGA-CN-4727-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.3889	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		HNSC_MUSE	TCGA-CV-7435-01A-11D-2129-08	TCGA-CV-7435-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.3733	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		HNSC_MUSE	TCGA-CR-6478-01A-11D-1870-08	TCGA-CR-6478-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E204*	0.5932	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E204* (Nonsense)		HNSC_MUSE	TCGA-QK-A8Z7-01A-11D-A391-08	TCGA-QK-A8Z7-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R283P	0.3261	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R283P (Missense)		HNSC_MUSE	TCGA-CN-A497-01A-11D-A24D-08	TCGA-CN-A497-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.G266*	0.3333	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266* (Nonsense)		HNSC_MUSE	TCGA-CN-A497-01A-11D-A24D-08	TCGA-CN-A497-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.3929	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		HNSC_MUSE	TCGA-IQ-7630-01A-11D-2078-08	TCGA-IQ-7630-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337C	0.6364	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337C (Missense)		HNSC_MUSE	TCGA-CN-4739-01A-02D-1512-08	TCGA-CN-4739-10A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110L	0.3373	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110L (Missense)		HNSC_MUSE	TCGA-CV-A465-01A-11D-A25Y-08	TCGA-CV-A465-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.5645	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173M (Missense)		HNSC_MUSE	TCGA-BA-A6DE-01A-22D-A31L-08	TCGA-BA-A6DE-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.2297	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		HNSC_MUSE	TCGA-CV-7104-01A-11D-2012-08	TCGA-CV-7104-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q38*	0.2231	260.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q38* (Nonsense)		HNSC_MUSE	TCGA-CV-7104-01A-11D-2012-08	TCGA-CV-7104-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.2059	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CV-A45W-01A-11D-A25D-08	TCGA-CV-A45W-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.2105	38.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		HNSC_MUSE	TCGA-CV-A45W-01A-11D-A25D-08	TCGA-CV-A45W-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.514	107.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		HNSC_MUSE	TCGA-UF-A718-01A-22D-A34J-08	TCGA-UF-A718-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176Y	0.3538	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176Y (Missense)		HNSC_MUSE	TCGA-CV-5440-01A-01D-1512-08	TCGA-CV-5440-11A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110L	0.4505	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110L (Missense)		HNSC_MUSE	TCGA-CV-5440-01A-01D-1512-08	TCGA-CV-5440-11A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.4842	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		HNSC_MUSE	TCGA-CV-6948-01A-11D-1912-08	TCGA-CV-6948-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2653	49.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-CN-6018-01A-11D-1683-08	TCGA-CN-6018-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.7798	109.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		HNSC_MUSE	TCGA-CV-5432-01A-02D-1683-08	TCGA-CV-5432-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2533	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-CV-6953-01A-11D-1912-08	TCGA-CV-6953-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110L	0.4138	87.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110L (Missense)		HNSC_MUSE	TCGA-QK-AA3K-01A-11D-A391-08	TCGA-QK-AA3K-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.1746	63.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		HNSC_MUSE	TCGA-CQ-5333-01A-01D-2394-08	TCGA-CQ-5333-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R213L	0.3784	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213L (Missense)		HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237V	0.3571	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237V (Missense)		HNSC_MUSE	TCGA-CR-6491-01A-11D-1870-08	TCGA-CR-6491-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.3231	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		HNSC_MUSE	TCGA-CR-6491-01A-11D-1870-08	TCGA-CR-6491-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.6333	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-CQ-6229-01A-11D-1912-08	TCGA-CQ-6229-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236C	0.5876	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y236C (Missense)		HNSC_MUSE	TCGA-BA-5555-01A-01D-1512-08	TCGA-BA-5555-10A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X32_splice	0.26	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X32_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A45X-01A-21D-A25D-08	TCGA-CV-A45X-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V218G	0.2273	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V218G (Missense)		HNSC_MUSE	TCGA-CQ-6218-01A-11D-1912-08	TCGA-CQ-6218-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E258D	0.4872	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E258D (Missense)		HNSC_MUSE	TCGA-BA-4074-01A-01D-1434-08	TCGA-BA-4074-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163C	0.9181	171.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163C (Missense)		HNSC_MUSE	TCGA-CV-7446-01A-11D-2229-08	TCGA-CV-7446-10A-01D-2229-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.4186	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		HNSC_MUSE	TCGA-CN-6023-01A-11D-1683-08	TCGA-CN-6023-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A276D	0.3396	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A276D (Missense)		HNSC_MUSE	TCGA-BA-A4II-01A-11D-A25Y-08	TCGA-BA-A4II-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V157F	0.6	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V157F (Missense)		HNSC_MUSE	TCGA-DQ-5629-01A-01D-1870-08	TCGA-DQ-5629-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173M	0.3804	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173M (Missense)		HNSC_MUSE	TCGA-CV-7242-01A-11D-2012-08	TCGA-CV-7242-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V173L	0.6	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V173L (Missense)		HNSC_MUSE	TCGA-CV-6936-01A-11D-1912-08	TCGA-CV-6936-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278S	0.8182	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278S (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E294*	0.4143	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294* (Nonsense)		HNSC_MUSE	TCGA-QK-A8ZB-01A-11D-A391-08	TCGA-QK-A8ZB-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R196P	0.5366	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196P (Missense)		HNSC_MUSE	TCGA-CX-7219-01A-11D-2012-08	TCGA-CX-7219-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E286K	0.5111	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E286K (Missense)		HNSC_MUSE	TCGA-CV-5977-01A-11D-1683-08	TCGA-CV-5977-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.359	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-CR-7368-01A-11D-2129-08	TCGA-CR-7368-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3654	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-CV-5979-01A-11D-1683-08	TCGA-CV-5979-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L194R	0.561	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L194R (Missense)		HNSC_MUSE	TCGA-D6-A4ZB-01A-11D-A25D-08	TCGA-D6-A4ZB-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.8333	120.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266E	0.4211	19.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266E (Missense)		HNSC_MUSE	TCGA-CV-7102-01A-11D-2012-08	TCGA-CV-7102-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.3521	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		HNSC_MUSE	TCGA-IQ-A61H-01A-11D-A30E-08	TCGA-IQ-A61H-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.N239D	0.3922	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N239D (Missense)		HNSC_MUSE	TCGA-MT-A51W-01A-21D-A25Y-08	TCGA-MT-A51W-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.3214	28.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A45Z-01A-21D-A25D-08	TCGA-CV-A45Z-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.5476	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-CR-7380-01A-11D-2012-08	TCGA-CR-7380-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P278S	0.62	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P278S (Missense)		HNSC_MUSE	TCGA-CV-A45R-01A-11D-A24D-08	TCGA-CV-A45R-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193L	0.5962	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193L (Missense)		HNSC_MUSE	TCGA-CV-6945-01A-11D-1912-08	TCGA-CV-6945-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266R	0.3889	18.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266R (Missense)		HNSC_MUSE	TCGA-CQ-5330-01A-01D-1683-08	TCGA-CQ-5330-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.3263	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CN-6995-01A-31D-2012-08	TCGA-CN-6995-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V272M	0.6538	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V272M (Missense)		HNSC_MUSE	TCGA-T2-A6WZ-01A-21D-A34J-08	TCGA-T2-A6WZ-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.2714	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		HNSC_MUSE	TCGA-T2-A6WZ-01A-21D-A34J-08	TCGA-T2-A6WZ-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.8431	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-BB-4227-01A-01D-1870-08	TCGA-BB-4227-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q136*	0.8961	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136* (Nonsense)		HNSC_MUSE	TCGA-CN-6997-01A-11D-2012-08	TCGA-CN-6997-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V216M	0.7273	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V216M (Missense)		HNSC_MUSE	TCGA-CR-7365-01A-11D-2012-08	TCGA-CR-7365-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179R	0.3235	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179R (Missense)		HNSC_MUSE	TCGA-HD-8635-01A-11D-2394-08	TCGA-HD-8635-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238F	0.2371	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238F (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R156P	0.2899	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R156P (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E271K	0.9459	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E271K (Missense)		HNSC_MUSE	TCGA-KU-A66T-01A-11D-A30E-08	TCGA-KU-A66T-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238S	0.2935	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238S (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.3889	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		HNSC_MUSE	TCGA-D6-6825-01A-21D-1912-08	TCGA-D6-6825-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.6265	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-IQ-A61K-01A-11D-A30E-08	TCGA-IQ-A61K-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.253	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-UF-A71A-01A-22D-A34J-08	TCGA-UF-A71A-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.3864	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		HNSC_MUSE	TCGA-UF-A71A-01A-22D-A34J-08	TCGA-UF-A71A-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.299	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X126_splice	0.3125	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X126_splice (Splice Site)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E294*	0.5429	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294* (Nonsense)		HNSC_MUSE	TCGA-CQ-A4C6-01A-11D-A25D-08	TCGA-CQ-A4C6-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193Y	0.4868	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193Y (Missense)		HNSC_MUSE	TCGA-P3-A5QA-01A-11D-A28R-08	TCGA-P3-A5QA-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V172F	0.4559	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V172F (Missense)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.L201*	0.1719	64.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L201* (Nonsense)		HNSC_MUSE	TCGA-BA-5557-01A-01D-1512-08	TCGA-BA-5557-10A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F341L	0.1636	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F341L (Missense)		HNSC_MUSE	TCGA-CV-A468-01A-11D-A25Y-08	TCGA-CV-A468-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193L	0.7059	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193L (Missense)		HNSC_MUSE	TCGA-QK-A8ZA-01A-11D-A391-08	TCGA-QK-A8ZA-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.1856	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		HNSC_MUSE	TCGA-CQ-5331-01A-02D-1870-08	TCGA-CQ-5331-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163H	0.3721	129.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163H (Missense)		HNSC_MUSE	TCGA-D6-8568-01A-11D-2394-08	TCGA-D6-8568-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176Y	0.1792	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176Y (Missense)		HNSC_MUSE	TCGA-BA-A6DI-01A-11D-A30E-08	TCGA-BA-A6DI-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X331_splice	0.4903	155.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X331_splice (Splice Site)		HNSC_MUSE	TCGA-CR-7383-01A-11D-2129-08	TCGA-CR-7383-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M246I	0.2817	71.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M246I (Missense)		HNSC_MUSE	TCGA-CV-A6K2-01A-11D-A31L-08	TCGA-CV-A6K2-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G105C	0.4658	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G105C (Missense)		HNSC_MUSE	TCGA-CV-7413-01A-11D-2078-08	TCGA-CV-7413-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M237I	0.451	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M237I (Missense)		HNSC_MUSE	TCGA-CN-4735-01A-01D-1434-08	TCGA-CN-4735-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E224D	0.5	16.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E224D (Missense)		HNSC_MUSE	TCGA-CN-6020-01A-11D-1683-08	TCGA-CN-6020-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G105V	0.2785	158.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G105V (Missense)		HNSC_MUSE	TCGA-BA-A6DL-01A-21D-A30E-08	TCGA-BA-A6DL-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R196P	0.5455	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196P (Missense)		HNSC_MUSE	TCGA-P3-A6T5-01A-11D-A34J-08	TCGA-P3-A6T5-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193R	0.8148	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193R (Missense)		HNSC_MUSE	TCGA-CV-6962-01A-11D-1912-08	TCGA-CV-6962-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.8043	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		HNSC_MUSE	TCGA-QK-AA3J-01A-11D-A391-08	TCGA-QK-AA3J-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E171*	0.3696	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171* (Nonsense)		HNSC_MUSE	TCGA-CV-7101-01A-11D-2012-08	TCGA-CV-7101-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E171*	0.5769	130.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E171* (Nonsense)		HNSC_MUSE	TCGA-CN-4731-01A-01D-1434-08	TCGA-CN-4731-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.5432	81.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		HNSC_MUSE	TCGA-IQ-A6SH-01A-12D-A34J-08	TCGA-IQ-A6SH-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.1833	120.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-UF-A7JA-01A-12D-A34J-08	TCGA-UF-A7JA-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E68*	0.1331	263.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E68* (Nonsense)		HNSC_MUSE	TCGA-UF-A7JA-01A-12D-A34J-08	TCGA-UF-A7JA-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151S	0.3168	101.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151S (Missense)		HNSC_MUSE	TCGA-F7-A620-01A-11D-A28R-08	TCGA-F7-A620-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.375	40.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		HNSC_MUSE	TCGA-CV-6933-01A-11D-1912-08	TCGA-CV-6933-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193P	0.4706	68.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193P (Missense)		HNSC_MUSE	TCGA-WA-A7GZ-01A-11D-A34J-08	TCGA-WA-A7GZ-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.L137Q	0.566	53.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.L137Q (Missense)		HNSC_MUSE	TCGA-D6-6823-01A-11D-1912-08	TCGA-D6-6823-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q331H	0.2949	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331H (Missense)		HNSC_MUSE	TCGA-F7-A50G-01A-11D-A25Y-08	TCGA-F7-A50G-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.2444	45.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-CN-6013-01A-11D-1683-08	TCGA-CN-6013-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X25_splice	0.3519	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X25_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A45Q-01A-11D-A24D-08	TCGA-CV-A45Q-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.K132N	0.5	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K132N (Missense)		HNSC_MUSE	TCGA-CV-7247-01A-11D-2012-08	TCGA-CV-7247-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.3864	44.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-UF-A7JS-01A-11D-A34J-08	TCGA-UF-A7JS-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.3826	115.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-UF-A7JS-01A-11D-A34J-08	TCGA-UF-A7JS-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236D	0.5714	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y236D (Missense)		HNSC_MUSE	TCGA-DQ-7592-01A-11D-2078-08	TCGA-DQ-7592-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.2764	123.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		HNSC_MUSE	TCGA-HD-A6HZ-01A-12D-A31L-08	TCGA-HD-A6HZ-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y220C	0.4	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y220C (Missense)		HNSC_MUSE	TCGA-CV-5976-01A-11D-1683-08	TCGA-CV-5976-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R110L	0.2537	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R110L (Missense)		HNSC_MUSE	TCGA-CV-5976-01A-11D-1683-08	TCGA-CV-5976-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.32	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-BA-A6DD-01A-12D-A31L-08	TCGA-BA-A6DD-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.2364	110.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-BA-5558-01A-01D-1512-08	TCGA-BA-5558-10A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Y205*	0.4521	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y205* (Nonsense)		HNSC_MUSE	TCGA-P3-A6T4-01A-11D-A34J-08	TCGA-P3-A6T4-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.W91*	0.7928	111.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.W91* (Nonsense)		HNSC_MUSE	TCGA-CV-5435-01A-01D-1683-08	TCGA-CV-5435-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.4071	113.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		HNSC_MUSE	TCGA-H7-A6C5-01A-11D-A30E-08	TCGA-H7-A6C5-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X367_splice	0.4615	13.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X367_splice (Splice Site)		HNSC_MUSE	TCGA-BA-A6D8-01A-31D-A31L-08	TCGA-BA-A6D8-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X33_splice	0.078	282.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X33_splice (Splice Site)		HNSC_MUSE	TCGA-CN-4740-01A-01D-1434-08	TCGA-CN-4740-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193P	0.1385	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193P (Missense)		HNSC_MUSE	TCGA-CN-4736-01A-01D-1434-08	TCGA-CN-4736-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.2065	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		HNSC_MUSE	TCGA-CN-4736-01A-01D-1434-08	TCGA-CN-4736-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.597	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-UF-A7JD-01A-11D-A34J-08	TCGA-UF-A7JD-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.2353	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A6JU-01A-11D-A31L-08	TCGA-CV-A6JU-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.F270C	0.5	30.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.F270C (Missense)		HNSC_MUSE	TCGA-CV-6951-01A-11D-1912-08	TCGA-CV-6951-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T211I	0.3333	42.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T211I (Missense)		HNSC_MUSE	TCGA-CV-6951-01A-11D-1912-08	TCGA-CV-6951-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.I251N	0.2661	109.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.I251N (Missense)		HNSC_MUSE	TCGA-P3-A6T0-01A-12D-A34J-08	TCGA-P3-A6T0-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.4848	33.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CV-7090-01A-11D-2012-08	TCGA-CV-7090-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C277G	0.4839	31.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C277G (Missense)		HNSC_MUSE	TCGA-D6-8569-01A-11D-2394-08	TCGA-D6-8569-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y126C	0.6471	34.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y126C (Missense)		HNSC_MUSE	TCGA-CV-7430-01A-11D-2129-08	TCGA-CV-7430-10A-01D-2129-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245V	0.4176	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245V (Missense)		HNSC_MUSE	TCGA-CN-5373-01A-01D-1434-08	TCGA-CN-5373-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C238F	0.3976	83.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C238F (Missense)		HNSC_MUSE	TCGA-CN-6996-01A-11D-1912-08	TCGA-CN-6996-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R306*	0.6465	99.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R306* (Nonsense)		HNSC_MUSE	TCGA-CN-6998-01A-23D-2012-08	TCGA-CN-6998-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275F	0.4571	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275F (Missense)		HNSC_MUSE	TCGA-CV-6952-01A-11D-1912-08	TCGA-CV-6952-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y234C	0.6104	77.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y234C (Missense)		HNSC_MUSE	TCGA-CV-7235-01A-11D-2012-08	TCGA-CV-7235-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337C	0.4	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337C (Missense)		HNSC_MUSE	TCGA-D6-A6EQ-01A-11D-A31L-08	TCGA-D6-A6EQ-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.26	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-CV-7180-01A-11D-2012-08	TCGA-CV-7180-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H193L	0.5618	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H193L (Missense)		HNSC_MUSE	TCGA-CN-5365-01A-01D-1434-08	TCGA-CN-5365-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.2418	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		HNSC_MUSE	TCGA-BB-4224-01A-01D-1434-08	TCGA-BB-4224-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G266E	0.3158	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G266E (Missense)		HNSC_MUSE	TCGA-CV-5436-01A-01D-1512-08	TCGA-CV-5436-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E56*	0.3051	331.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E56* (Nonsense)		HNSC_MUSE	TCGA-CV-5436-01A-01D-1512-08	TCGA-CV-5436-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337L	0.6486	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R337L (Missense)		HNSC_MUSE	TCGA-CR-7398-01A-11D-2012-08	TCGA-CR-7398-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.V143M	0.3765	85.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.V143M (Missense)		HNSC_MUSE	TCGA-BA-5151-01A-01D-1434-08	TCGA-BA-5151-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X225_splice	0.863	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X225_splice (Splice Site)		HNSC_MUSE	TCGA-BA-4078-01A-01D-1434-08	TCGA-BA-4078-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242Y	0.354	113.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242Y (Missense)		HNSC_MUSE	TCGA-BA-6870-01A-11D-1870-08	TCGA-BA-6870-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.2188	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CN-4733-01A-02D-1870-08	TCGA-CN-4733-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q144*	0.2239	67.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q144* (Nonsense)		HNSC_MUSE	TCGA-QK-A6VC-01A-23D-A34J-08	TCGA-QK-A6VC-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X307_splice	0.5949	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X307_splice (Splice Site)		HNSC_MUSE	TCGA-BB-A6UO-01A-12D-A34J-08	TCGA-BB-A6UO-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.T256I	0.2921	89.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.T256I (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.N239D	0.2083	96.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.N239D (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q167*	0.5949	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q167* (Nonsense)		HNSC_MUSE	TCGA-BA-A8YP-01A-11D-A391-08	TCGA-BA-A8YP-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.373	126.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		HNSC_MUSE	TCGA-IQ-A61J-01A-11D-A30E-08	TCGA-IQ-A61J-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E68*	0.6196	276.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E68* (Nonsense)		HNSC_MUSE	TCGA-D6-A74Q-01A-11D-A34J-08	TCGA-D6-A74Q-10A-02D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.2	25.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		HNSC_MUSE	TCGA-UF-A71B-01A-12D-A34J-08	TCGA-UF-A71B-10B-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q192*	0.3729	59.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q192* (Nonsense)		HNSC_MUSE	TCGA-RS-A6TO-01A-32D-A34J-08	TCGA-RS-A6TO-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E298*	0.68	50.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E298* (Nonsense)		HNSC_MUSE	TCGA-CN-A63W-01A-11D-A30E-08	TCGA-CN-A63W-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q52*	0.2586	290.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q52* (Nonsense)		HNSC_MUSE	TCGA-CV-7252-01A-11D-2012-08	TCGA-CV-7252-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q136E	0.2	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136E (Missense)		HNSC_MUSE	TCGA-CQ-A4CD-01A-21D-A25D-08	TCGA-CQ-A4CD-10A-01D-A25E-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273C	0.4375	32.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273C (Missense)		HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248Q	0.3765	85.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248Q (Missense)		HNSC_MUSE	TCGA-F7-A61S-01A-11D-A28R-08	TCGA-F7-A61S-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E294*	0.2667	90.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E294* (Nonsense)		HNSC_MUSE	TCGA-CN-4742-01A-02D-1512-08	TCGA-CN-4742-10A-01D-1512-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X261_splice	0.2364	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X261_splice (Splice Site)		HNSC_MUSE	TCGA-CN-6022-01A-21D-1683-08	TCGA-CN-6022-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.2759	87.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-CN-6022-01A-21D-1683-08	TCGA-CN-6022-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R283P	0.4727	55.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R283P (Missense)		HNSC_MUSE	TCGA-P3-A6T2-01A-11D-A34J-08	TCGA-P3-A6T2-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.D259N	0.3929	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.D259N (Missense)		HNSC_MUSE	TCGA-P3-A6T2-01A-11D-A34J-08	TCGA-P3-A6T2-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.K101*	0.814	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.K101* (Nonsense)		HNSC_MUSE	TCGA-CQ-6228-01A-11D-1912-08	TCGA-CQ-6228-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X125_splice	0.3911	179.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X125_splice (Splice Site)		HNSC_MUSE	TCGA-CN-4726-01A-01D-1434-08	TCGA-CN-4726-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.1867	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-D6-6517-01A-11D-1870-08	TCGA-D6-6517-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E285K	0.7568	37.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E285K (Missense)		HNSC_MUSE	TCGA-CV-7414-01A-11D-2078-08	TCGA-CV-7414-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M246I	0.1795	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M246I (Missense)		HNSC_MUSE	TCGA-CV-7407-01A-11D-2078-08	TCGA-CV-7407-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.2157	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CV-7407-01A-11D-2078-08	TCGA-CV-7407-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y163C	0.2174	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163C (Missense)		HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.E56*	0.1943	283.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E56* (Nonsense)		HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176F	0.2967	91.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176F (Missense)		HNSC_MUSE	TCGA-CV-A6JZ-01A-11D-A31L-08	TCGA-CV-A6JZ-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.6207	58.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CV-7416-01A-11D-2078-08	TCGA-CV-7416-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.6512	43.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-CX-7082-01A-11D-2012-08	TCGA-CX-7082-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176S	0.7561	41.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176S (Missense)		HNSC_MUSE	TCGA-CQ-6225-01A-11D-1912-08	TCGA-CQ-6225-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.6111	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-CV-7245-01A-11D-2012-08	TCGA-CV-7245-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S106R	0.6081	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S106R (Missense)		HNSC_MUSE	TCGA-CR-7390-01A-11D-2012-08	TCGA-CR-7390-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.5143	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CQ-5329-01A-01D-1683-08	TCGA-CQ-5329-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.S166*	0.2154	65.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S166* (Nonsense)		HNSC_MUSE	TCGA-CQ-5334-01A-01D-1683-08	TCGA-CQ-5334-10A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Q331*	0.1918	73.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q331* (Nonsense)		HNSC_MUSE	TCGA-CV-6942-01A-21D-2012-08	TCGA-CV-6942-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179Y	0.5362	69.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179Y (Missense)		HNSC_MUSE	TCGA-HD-7229-01A-11D-2012-08	TCGA-HD-7229-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R158L	0.5395	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R158L (Missense)		HNSC_MUSE	TCGA-QK-A8Z8-01A-11D-A391-08	TCGA-QK-A8Z8-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R282W	0.4286	21.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R282W (Missense)		HNSC_MUSE	TCGA-IQ-A6SG-01A-12D-A34J-08	TCGA-IQ-A6SG-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245D	0.2857	56.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245D (Missense)		HNSC_MUSE	TCGA-C9-A480-01A-12D-A24D-08	TCGA-C9-A480-10A-01D-A24F-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R248W	0.1733	75.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R248W (Missense)		HNSC_MUSE	TCGA-BB-A5HZ-01A-21D-A28R-08	TCGA-BB-A5HZ-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.E180K	0.2526	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.E180K (Missense)		HNSC_MUSE	TCGA-BB-A5HZ-01A-21D-A28R-08	TCGA-BB-A5HZ-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R273H	0.25	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R273H (Missense)		HNSC_MUSE	TCGA-CV-6436-01A-11D-1683-08	TCGA-CV-6436-11A-01D-1683-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X224_splice	0.6087	46.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X224_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R196*	0.3	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R196* (Nonsense)		HNSC_MUSE	TCGA-H7-A6C4-01A-11D-A30E-08	TCGA-H7-A6C4-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.2179	78.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		HNSC_MUSE	TCGA-CQ-5326-01A-01D-1870-08	TCGA-CQ-5326-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X32_splice	0.1368	95.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X32_splice (Splice Site)		HNSC_MUSE	TCGA-CQ-5326-01A-01D-1870-08	TCGA-CQ-5326-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R283P	0.2456	57.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R283P (Missense)		HNSC_MUSE	TCGA-CN-6994-01A-11D-1912-08	TCGA-CN-6994-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R175H	0.3158	76.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R175H (Missense)		HNSC_MUSE	TCGA-CN-6994-01A-11D-1912-08	TCGA-CN-6994-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.M133K	0.5429	35.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.M133K (Missense)		HNSC_MUSE	TCGA-CV-7415-01A-11D-2078-08	TCGA-CV-7415-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151T	0.4444	72.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151T (Missense)		HNSC_MUSE	TCGA-CV-5966-01A-11D-1683-08	TCGA-CV-5966-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Y236C	0.2833	60.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y236C (Missense)		HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C275F	0.2549	51.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C275F (Missense)		HNSC_MUSE	TCGA-CN-4725-01A-01D-1434-08	TCGA-CN-4725-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S127F	0.5	20.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S127F (Missense)		HNSC_MUSE	TCGA-CV-7421-01A-11D-2078-08	TCGA-CV-7421-10A-01D-2078-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C176Y	0.4516	62.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C176Y (Missense)		HNSC_MUSE	TCGA-BB-A5HU-01A-11D-A28R-08	TCGA-BB-A5HU-10A-01D-A28U-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Y163*	0.5217	92.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y163* (Nonsense)		HNSC_MUSE	TCGA-P3-A6SX-01A-11D-A34J-08	TCGA-P3-A6SX-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.Y103*	0.378	82.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Y103* (Nonsense)		HNSC_MUSE	TCGA-CV-7263-01A-11D-2012-08	TCGA-CV-7263-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G105V	0.1735	98.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G105V (Missense)		HNSC_MUSE	TCGA-CN-A6V3-01A-12D-A34J-08	TCGA-CN-A6V3-10A-01D-A34M-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.Q136P	0.3788	66.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.Q136P (Missense)		HNSC_MUSE	TCGA-BA-4076-01A-01D-1434-08	TCGA-BA-4076-10A-01D-1434-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.H179N	0.4177	79.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.H179N (Missense)		HNSC_MUSE	TCGA-CQ-7063-01A-11D-2394-08	TCGA-CQ-7063-10A-01D-2394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.3302	106.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		HNSC_MUSE	TCGA-DQ-5631-01A-01D-1870-08	TCGA-DQ-5631-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.S241C	0.8143	70.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.S241C (Missense)		HNSC_MUSE	TCGA-IQ-A61G-01A-11D-A30E-08	TCGA-IQ-A61G-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.C242S	0.7524	105.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.C242S (Missense)		HNSC_MUSE	TCGA-CV-6935-01A-11D-1912-08	TCGA-CV-6935-10A-01D-1912-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.2045	88.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R213* (Nonsense)		HNSC_MUSE	TCGA-IQ-A61O-01A-11D-A30E-08	TCGA-IQ-A61O-10A-01D-A30H-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Splice Site	p.X187_splice	0.433	97.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.X187_splice (Splice Site)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R249S	0.5455	99.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.R249S (Missense)		HNSC_MUSE	TCGA-QK-A8Z9-01B-11D-A391-08	TCGA-QK-A8Z9-10A-01D-A394-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.P151H	0.6216	74.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.P151H (Missense)		HNSC_MUSE	TCGA-CV-7177-01A-11D-2012-08	TCGA-CV-7177-10A-01D-2013-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.G245S	0.3672	128.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.G245S (Missense)		HNSC_MUSE	TCGA-BA-5152-01A-02D-1870-08	TCGA-BA-5152-10A-01D-1870-08
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.A159V	0.5	52.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					TP53 p.A159V (Missense)		HNSC_MUSE	TCGA-CQ-6223-01A-11D-1912-08	TCGA-CQ-6223-10A-01D-1912-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.I313V	0.2273	132.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.I313V (Missense)		HNSC_MUSE	TCGA-IQ-A61L-01A-11D-A30E-08	TCGA-IQ-A61L-10A-01D-A30H-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.A993P	0.5529	85.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.A993P (Missense)		HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.R533S	0.2258	62.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.R533S (Missense)		HNSC_MUSE	TCGA-BA-A6DD-01A-12D-A31L-08	TCGA-BA-A6DD-10A-01D-A31J-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.Y70H	0.2727	264.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.Y70H (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Missense	p.I360V	0.2941	51.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.I360V (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.F57L	0.3246	114.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.F57L (Missense)		HNSC_MUSE	TCGA-CQ-5332-01A-01D-1683-08	TCGA-CQ-5332-10A-01D-1683-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.Q157H	0.3333	12.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.Q157H (Missense)		HNSC_MUSE	TCGA-C9-A47Z-01A-11D-A24D-08	TCGA-C9-A47Z-10A-01D-A24F-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E323Q	0.82	50.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E323Q (Missense)		HNSC_MUSE	TCGA-CV-A6JE-01A-11D-A31L-08	TCGA-CV-A6JE-10A-01D-A31J-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.S94L	0.3261	46.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.S94L (Missense)		HNSC_MUSE	TCGA-CN-A6V6-01A-12D-A34J-08	TCGA-CN-A6V6-10A-01D-A34M-08
Investigate Actionability		Clinical evidence		Somatic Variant	MAP2K2	Missense	p.S127L	0.1159	69.0	0.0	0.0									Investigate Actionability	Trametinib	MEK inhibition	Targeted therapy	MEK2 Q60P was observed in a patient's trametinib resistant tumor but not pretreatment tumor.	"Wagle, Nikhil, et al. ""MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition."" Cancer discovery 4.1 (2014): 61-68."	https://doi.org/10.1158/2159-8290.CD-13-0631										MAP2K2 p.S127L (Missense)		HNSC_MUSE	TCGA-CR-6474-01A-11D-1870-08	TCGA-CR-6474-10A-01D-1870-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.E340K	0.4545	44.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.E340K (Missense)		HNSC_MUSE	TCGA-P3-A5Q5-01A-11D-A28R-08	TCGA-P3-A5Q5-10A-01D-A28U-08
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.R13G	0.2439	41.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220										AR p.R13G (Missense)		HNSC_MUSE	TCGA-P3-A6T4-01A-11D-A34J-08	TCGA-P3-A6T4-10A-01D-A34M-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.S1039R	0.2041	49.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.S1039R (Missense)		HNSC_MUSE	TCGA-CQ-5332-01A-01D-1683-08	TCGA-CQ-5332-10A-01D-1683-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P500L	0.3085	94.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P500L (Missense)		HNSC_MUSE	TCGA-CQ-7072-01A-21D-A30E-08	TCGA-CQ-7072-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.W893R	0.4483	58.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.W893R (Missense)		HNSC_MUSE	TCGA-CV-A6JE-01A-11D-A31L-08	TCGA-CV-A6JE-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P299R	0.1579	76.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.P299R (Missense)		HNSC_MUSE	TCGA-CR-6474-01A-11D-1870-08	TCGA-CR-6474-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D204E	0.386	57.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D204E (Missense)		HNSC_MUSE	TCGA-CN-A49A-01A-11D-A24D-08	TCGA-CN-A49A-10A-01D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D1294H	0.1545	110.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.D1294H (Missense)		HNSC_MUSE	TCGA-CN-5366-01A-01D-1434-08	TCGA-CN-5366-10A-01D-1434-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.E491D	0.113	115.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E491D (Missense)		HNSC_MUSE	TCGA-CN-4729-01A-01D-1434-08	TCGA-CN-4729-10A-01D-1434-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Nonsense	p.Q593*	0.2083	24.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.Q593* (Nonsense)		HNSC_MUSE	TCGA-HD-A4C1-01A-11D-A24D-08	TCGA-HD-A4C1-10A-02D-A24F-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Nonsense	p.E371*	0.3095	42.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.E371* (Nonsense)		HNSC_MUSE	TCGA-UF-A718-01A-22D-A34J-08	TCGA-UF-A718-10A-01D-A34M-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.Q374L	0.175	40.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.Q374L (Missense)		HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.Y101C	0.6061	66.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.Y101C (Missense)		HNSC_MUSE	TCGA-CV-6950-01A-11D-1912-08	TCGA-CV-6950-10A-01D-1912-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.G150V	0.1124	178.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.G150V (Missense)		HNSC_MUSE	TCGA-CV-A45Y-01A-11D-A25D-08	TCGA-CV-A45Y-10A-01D-A25E-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.R729Q	0.5167	60.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.R729Q (Missense)		HNSC_MUSE	TCGA-CV-6936-01A-11D-1912-08	TCGA-CV-6936-10A-01D-1912-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.Q404*	0.4694	49.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.Q404* (Nonsense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.Q965R	0.4754	122.0	0.0	0.0																Investigate Actionability	0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SETBP1 p.Q965R (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.S689C	0.1864	59.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.S689C (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Splice Site	p.X1581_splice	0.2381	21.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.X1581_splice (Splice Site)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Investigate Actionability			Guideline	Somatic Variant	BCOR	Nonsense	p.S268*	0.2	25.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					BCOR p.S268* (Nonsense)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.W898*	0.3566	129.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.W898* (Nonsense)		HNSC_MUSE	TCGA-D6-A6ES-01A-12D-A31L-08	TCGA-D6-A6ES-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	DNMT3A	Missense	p.P419L	0.1216	74.0	0.0	0.0																Investigate Actionability	0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					DNMT3A p.P419L (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.E1160K	0.0714	182.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.E1160K (Missense)		HNSC_MUSE	TCGA-CN-A6V1-01A-12D-A34J-08	TCGA-CN-A6V1-10B-01D-A34M-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.R693*	0.3115	61.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R693* (Nonsense)		HNSC_MUSE	TCGA-CV-A6JY-01A-11D-A31L-08	TCGA-CV-A6JY-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Missense	p.S286C	0.1442	319.0	0.0	0.0																Investigate Actionability	1		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					SF3B1 p.S286C (Missense)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Nonsense	p.E1006*	0.3864	88.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E1006* (Nonsense)		HNSC_MUSE	TCGA-CV-7177-01A-11D-2012-08	TCGA-CV-7177-10A-01D-2013-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.E1042K	0.5556	63.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.E1042K (Missense)		HNSC_MUSE	TCGA-CN-4734-01A-01D-1434-08	TCGA-CN-4734-10A-01D-1434-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.R122H	0.2949	78.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.R122H (Missense)		HNSC_MUSE	TCGA-P3-A5QF-01A-11D-A28R-08	TCGA-P3-A5QF-10A-01D-A28U-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.C243Y	0.3118	263.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.C243Y (Missense)		HNSC_MUSE	TCGA-CN-5356-01A-01D-1434-08	TCGA-CN-5356-10A-01D-1434-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.I67M	0.191	89.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.I67M (Missense)		HNSC_MUSE	TCGA-IQ-A61L-01A-11D-A30E-08	TCGA-IQ-A61L-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.P727T	0.3516	91.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.P727T (Missense)		HNSC_MUSE	TCGA-CV-7104-01A-11D-2012-08	TCGA-CV-7104-10A-01D-2013-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.R1134S	0.3956	91.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.R1134S (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Missense	p.V342I	0.2857	35.0	0.0	0.0																Investigate Actionability	0	In a retrospective study of 244 patients, significantly more patients with a JAK2 V617F variant than without had complications (secondary fibrosis, hemorrhage, and thrombosis) and had received cytoreductive treatment.	Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-90.	https://doi.org/10.1056/NEJMoa051113					JAK2 p.V342I (Missense)		HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.D28H	0.6176	34.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.D28H (Missense)		HNSC_MUSE	TCGA-CV-7421-01A-11D-2078-08	TCGA-CV-7421-10A-01D-2078-08
Investigate Actionability			Clinical evidence	Somatic Variant	BCOR	Missense	p.K150R	0.5	70.0	0.0	0.0																Investigate Actionability	0	More frequent in Chronic Myelomonocytic Leukemia.	O'Brien C, Wallin JJ, Sampath D, et al. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 2010;16(14):3670-83.	https://doi.org/10.1158/1078-0432.CCR-09-2828					BCOR p.K150R (Missense)		HNSC_MUSE	TCGA-DQ-5631-01A-01D-1870-08	TCGA-DQ-5631-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.G1492R	0.2368	76.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.G1492R (Missense)	1	HNSC_MUSE	TCGA-CV-7097-01A-11D-2012-08	TCGA-CV-7097-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R664G	0.1453	117.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R664G (Missense)	1	HNSC_MUSE	TCGA-CV-7248-01A-11D-2012-08	TCGA-CV-7248-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.R2861T	0.2584	89.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.R2861T (Missense)	0	HNSC_MUSE	TCGA-T3-A92N-01A-11D-A391-08	TCGA-T3-A92N-10A-01D-A394-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.D853N	0.2759	203.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.D853N (Missense)	1	HNSC_MUSE	TCGA-BA-6872-01A-11D-1870-08	TCGA-BA-6872-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.E230Q	0.375	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.E230Q (Missense)	1	HNSC_MUSE	TCGA-CV-7099-01A-41D-2012-08	TCGA-CV-7099-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.D1386N	0.2593	54.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.D1386N (Missense)	0	HNSC_MUSE	TCGA-UF-A7JK-01A-11D-A34J-08	TCGA-UF-A7JK-10A-01D-A34M-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E3342K	0.2558	43.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E3342K (Missense)	0	HNSC_MUSE	TCGA-CR-6473-01A-11D-1870-08	TCGA-CR-6473-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1645M	0.4783	138.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1645M (Missense)	1	HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E2175Q	0.2558	43.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2175Q (Missense)	0	HNSC_MUSE	TCGA-CQ-7071-01A-12D-A30E-08	TCGA-CQ-7071-10A-01D-A30H-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.I2105V	0.4643	28.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.I2105V (Missense)	0	HNSC_MUSE	TCGA-CV-5440-01A-01D-1512-08	TCGA-CV-5440-11A-01D-1512-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E1571K	0.6136	88.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E1571K (Missense)	0	HNSC_MUSE	TCGA-CV-5430-01A-02D-1683-08	TCGA-CV-5430-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E2903K	0.1471	34.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E2903K (Missense)	0	HNSC_MUSE	TCGA-CV-6936-01A-11D-1912-08	TCGA-CV-6936-10A-01D-1912-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.G500V	0.4426	61.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.G500V (Missense)	0	HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.K175N	0.1389	108.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.K175N (Missense)	1	HNSC_MUSE	TCGA-CV-A6K2-01A-11D-A31L-08	TCGA-CV-A6K2-10A-01D-A31J-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.E3393Q	0.1923	104.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.E3393Q (Missense)	0	HNSC_MUSE	TCGA-UF-A7JV-01A-11D-A34J-08	TCGA-UF-A7JV-10A-01D-A34M-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.R1737T	0.1192	151.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.R1737T (Missense)	1	HNSC_MUSE	TCGA-F7-A50J-01A-21D-A28R-08	TCGA-F7-A50J-10A-01D-A28U-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.F312C	0.3235	170.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.F312C (Missense)	0	HNSC_MUSE	TCGA-UF-A7JA-01A-12D-A34J-08	TCGA-UF-A7JA-10A-01D-A34M-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Splice Site	p.X101_splice	0.3667	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.X101_splice (Splice Site)	0	HNSC_MUSE	TCGA-D6-6823-01A-11D-1912-08	TCGA-D6-6823-10A-01D-1912-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.K3315N	0.3656	93.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.K3315N (Missense)	0	HNSC_MUSE	TCGA-CV-7430-01A-11D-2129-08	TCGA-CV-7430-10A-01D-2129-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3218F	0.0643	171.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3218F (Missense)	0	HNSC_MUSE	TCGA-T2-A6X0-01A-11D-A34J-08	TCGA-T2-A6X0-10B-01D-A34M-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA1	Missense	p.D1505N	0.2	55.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. 	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf. Revised November 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s018lbl.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA1 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA1 p.D1505N (Missense)	1	HNSC_MUSE	TCGA-CV-7245-01A-11D-2012-08	TCGA-CV-7245-10A-01D-2013-08
Investigate Actionability	FDA-Approved	Clinical evidence		Somatic Variant	BRCA2	Missense	p.S3231L	0.2283	127.0	0.0	0.0		Investigate Actionability	Niraparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for niraparib for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation or genominc instability and who have progressed more than six months after response to the last platinum-based chemotherapy.	GlaxoSmithKline. Zejula (niraparib) [package insert]. U.S. Food and Drug Administration website. www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf. Revised April 2020. Accessed October 15, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208447s015s017lbledt.pdf	Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	Secondary mutations in BRCA2 may confer resistance to PARP inhibition in ovarian cancer	Lheureux S, Bruce JP, Burnier JV, et al. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. J Clin Oncol. 2017;:JCO2016713677.	https://doi.org/10.1200/JCO.2016.71.3677										BRCA2 p.S3231L (Missense)	0	HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.E17K	0.4286	70.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.E17K (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.E190K	0.3827	81.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.E190K (Missense)		HNSC_MUSE	TCGA-BA-6873-01A-11D-1870-08	TCGA-BA-6873-10A-01D-1870-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.G310V	0.2528	178.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.G310V (Missense)		HNSC_MUSE	TCGA-HD-8224-01A-11D-2394-08	TCGA-HD-8224-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	IDH1	Missense	p.D220N	0.1121	107.0	0.0	0.0		Investigate Actionability	Ivosidenib	IDH1 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval for ivosidenib, a small molecule inhibitor of isocitrate dehydrogenase (IDH)1 on July 20, 2018, for treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML) with susceptible IDH1 mutation as detected by an FDA-approved test.	Agios Pharmaceuticals, Inc.. Tibsovo (ivosidenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf. Revised October 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211192s001lbl.pdf								Investigate Actionability	1	Mutation of IDH1 is associated with a survival benefit in patients treated with alkylating chemotherapy (but not untreated patients).	National Comprehensive Cancer Network. Central Nervous System Cancers NCCN Evidence Blocks for Gliomas (Version 1.2016). https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/cns_blocks.pdf					IDH1 p.D220N (Missense)		HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.C828F	0.1622	74.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.C828F (Missense)	0	HNSC_MUSE	TCGA-F7-7848-01A-11D-2129-08	TCGA-F7-7848-10A-01D-2129-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.R264W	0.2188	160.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.R264W (Missense)	1	HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.A745T	0.2545	224.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.A745T (Missense)	1	HNSC_MUSE	TCGA-CV-A463-01A-11D-A25Y-08	TCGA-CV-A463-10A-01D-A25Y-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Nonsense	p.S618*	0.2586	58.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S618* (Nonsense)	1	HNSC_MUSE	TCGA-CN-A49A-01A-11D-A24D-08	TCGA-CN-A49A-10A-01D-A24F-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S1115F	0.7164	67.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S1115F (Missense)	1	HNSC_MUSE	TCGA-CN-6011-01A-11D-1683-08	TCGA-CN-6011-10A-01D-1683-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.E234V	0.3494	83.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.E234V (Missense)	0	HNSC_MUSE	TCGA-CN-A642-01A-12D-A30E-08	TCGA-CN-A642-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.P18R	0.2121	99.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.P18R (Missense)	1	HNSC_MUSE	TCGA-CN-6988-01A-11D-1912-08	TCGA-CN-6988-10A-01D-1912-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.K484E	0.1765	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.K484E (Missense)	0	HNSC_MUSE	TCGA-CV-A45W-01A-11D-A25D-08	TCGA-CV-A45W-10A-01D-A25E-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.E384K	0.1308	130.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.E384K (Missense)	0	HNSC_MUSE	TCGA-BA-A4IG-01A-11D-A25Y-08	TCGA-BA-A4IG-10A-01D-A25Y-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51C	Missense	p.K84M	0.2821	78.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51C p.K84M (Missense)	1	HNSC_MUSE	TCGA-CV-A45R-01A-11D-A24D-08	TCGA-CV-A45R-10A-01D-A24F-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S309Y	0.2062	97.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S309Y (Missense)	1	HNSC_MUSE	TCGA-KU-A66T-01A-11D-A30E-08	TCGA-KU-A66T-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.G750V	0.1746	315.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.G750V (Missense)	1	HNSC_MUSE	TCGA-CR-7383-01A-11D-2129-08	TCGA-CR-7383-10A-01D-2129-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S1063W	0.1209	182.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S1063W (Missense)	1	HNSC_MUSE	TCGA-CV-A6K2-01A-11D-A31L-08	TCGA-CV-A6K2-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.S489F	0.1111	207.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.S489F (Missense)	0	HNSC_MUSE	TCGA-CV-6962-01A-11D-1912-08	TCGA-CV-6962-10A-01D-1912-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.P300T	0.2249	209.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.P300T (Missense)	0	HNSC_MUSE	TCGA-CN-4731-01A-01D-1434-08	TCGA-CN-4731-10A-01D-1434-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.S310C	0.4308	65.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.S310C (Missense)	0	HNSC_MUSE	TCGA-CN-6013-01A-11D-1683-08	TCGA-CN-6013-10A-01D-1683-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Splice Site	p.X831_splice	0.209	67.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.X831_splice (Splice Site)	1	HNSC_MUSE	TCGA-F7-A61V-01A-11D-A28R-08	TCGA-F7-A61V-10A-01D-A28U-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BARD1	Missense	p.G698D	0.2203	59.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BARD1 p.G698D (Missense)	0	HNSC_MUSE	TCGA-D6-8569-01A-11D-2394-08	TCGA-D6-8569-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.S372F	0.2353	51.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.S372F (Missense)	0	HNSC_MUSE	TCGA-D6-8569-01A-11D-2394-08	TCGA-D6-8569-10A-01D-2394-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.T532I	0.2143	56.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					CHEK2 p.T532I (Missense)	0	HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	RAD51D	Missense	p.V208D	0.2111	90.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					RAD51D p.V208D (Missense)	0	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.T411A	0.2147	191.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.T411A (Missense)	1	HNSC_MUSE	TCGA-BA-5559-01A-01D-1512-08	TCGA-BA-5559-10A-01D-1512-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.S123L	0.2727	176.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.S123L (Missense)	1	HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	PALB2	Missense	p.N444S	0.3571	224.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					PALB2 p.N444S (Missense)	0	HNSC_MUSE	TCGA-CN-4725-01A-01D-1434-08	TCGA-CN-4725-10A-01D-1434-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.D280N	0.2	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.D280N (Missense)	1	HNSC_MUSE	TCGA-CR-5248-01A-01D-2012-08	TCGA-CR-5248-10A-01D-2013-08
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	BRIP1	Missense	p.E150K	0.17	100.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287					BRIP1 p.E150K (Missense)	1	HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.S503C	0.1935	155.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.S503C (Missense)	0	HNSC_MUSE	TCGA-CV-6441-01A-11D-1683-08	TCGA-CV-6441-11A-01D-1683-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.S512N	0.3333	24.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.S512N (Missense)	0	HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.I309V	0.3596	89.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.I309V (Missense)	0	HNSC_MUSE	TCGA-QK-A6VB-01A-12D-A34J-08	TCGA-QK-A6VB-10B-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.A618V	0.0684	190.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.A618V (Missense)	0	HNSC_MUSE	TCGA-WA-A7H4-01A-21D-A34J-08	TCGA-WA-A7H4-10A-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.R978H	0.1869	107.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.R978H (Missense)		HNSC_MUSE	TCGA-CX-A4AQ-01A-11D-A25D-08	TCGA-CX-A4AQ-10A-01D-A25E-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.E32Q	0.0811	111.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.E32Q (Missense)		HNSC_MUSE	TCGA-CV-7089-01A-11D-2012-08	TCGA-CV-7089-10A-01D-2013-08
Investigate Actionability	FDA-Approved			Somatic Variant	FANCL	Missense	p.I184T	0.0833	84.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	FANCL p.I184T (Missense)	0	HNSC_MUSE	TCGA-F7-8489-01A-31D-2394-08	TCGA-F7-8489-10A-01D-2394-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD51B	Nonsense	p.Q367*	0.2105	19.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD51B p.Q367* (Nonsense)	0	HNSC_MUSE	TCGA-T2-A6X2-01A-12D-A34J-08	TCGA-T2-A6X2-10B-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.F986S	0.1176	85.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.F986S (Missense)	0	HNSC_MUSE	TCGA-CN-4739-01A-02D-1512-08	TCGA-CN-4739-10A-01D-1512-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.P269T	0.3067	75.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.P269T (Missense)	0	HNSC_MUSE	TCGA-CR-7364-01A-11D-2012-08	TCGA-CR-7364-10A-01D-2013-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.D1105N	0.266	94.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.D1105N (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R980G	0.2288	118.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R980G (Missense)	0	HNSC_MUSE	TCGA-CV-7101-01A-11D-2012-08	TCGA-CV-7101-10A-01D-2013-08
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.F353L	0.0543	184.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	RAD54L p.F353L (Missense)	0	HNSC_MUSE	TCGA-CN-4740-01A-01D-1434-08	TCGA-CN-4740-10A-01D-1434-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC1	Missense	p.T1076A	0.187	123.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC1 p.T1076A (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	CDK12	Missense	p.R779H	0.2571	35.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf																	CDK12 p.R779H (Missense)	0	HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	FDA-Approved			Somatic Variant	TSC2	Missense	p.A607T	0.3173	104.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Everolimus is indicated for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex in adults and pediatric patients who are not candidates for curative surgical resection	Novartis Pharmaceuticals Corporation. Afinitor (everolimus) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf. Revised February 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022334s044,203985s016lbl.pdf																	TSC2 p.A607T (Missense)		HNSC_MUSE	TCGA-UF-A71B-01A-12D-A34J-08	TCGA-UF-A71B-10B-01D-A34M-08
Investigate Actionability	Guideline		Guideline	Somatic Variant	KIT	Nonsense	p.S244*	0.1871	139.0	0.0	0.0		Investigate Actionability	Imatinib	KIT inhibition	Targeted therapy	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf								Investigate Actionability	0	Mucosal Melanoma is a rare and highly aggressive neoplasm with poor prognosis. Patients with this disease and mutations with c-KIT mutations (KIT exon 11 or 13) may be sensitive to c-KIT inhibitors.	National Comprehensive Cancer Network. Very Advanced Head and Neck Cancers NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck_blocks.pdf					KIT p.S244* (Nonsense)	0	HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.R550*	0.1687	83.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.R550* (Nonsense)		HNSC_MUSE	TCGA-CV-A6JT-01A-11D-A31L-08	TCGA-CV-A6JT-10A-01D-A31J-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.S588*	0.2742	124.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.S588* (Nonsense)		HNSC_MUSE	TCGA-CN-5366-01A-01D-1434-08	TCGA-CN-5366-10A-01D-1434-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.R376*	0.219	137.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.R376* (Nonsense)	0	HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.G908C	0.4583	48.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G908C (Missense)		HNSC_MUSE	TCGA-BA-A6DL-01A-21D-A30E-08	TCGA-BA-A6DL-10A-01D-A30H-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Missense	p.K1052R	0.3465	101.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.K1052R (Missense)		HNSC_MUSE	TCGA-P3-A6T0-01A-12D-A34J-08	TCGA-P3-A6T0-10A-01D-A34M-08
Investigate Actionability	Guideline			Somatic Variant	PDGFRA	Nonsense	p.S227*	0.2071	140.0	0.0	0.0		Investigate Actionability	Imatinib	PDGF-R inhibition	Targeted therapy	Mutations in PDGFRA are associated with response to imatinib, with the exception of p.D842V.	National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors (GIST) NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/melanoma_blocks.pdf. Accessed August 10th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf																	PDGFRA p.S227* (Nonsense)	0	HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability	Guideline			Somatic Variant	TET2	Nonsense	p.G563*	0.2143	112.0	0.0	0.0		Investigate Actionability	Azacitidine	Hypomethylating agent chemotherapy	Chemotherapy	TET2 mutations are associated with an increased sensitivity to hypomethylating agents (such as AzaC). This increased sensitivity may be partially abrogated in the presence of ASXL1 mutations.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf																	TET2 p.G563* (Nonsense)		HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.P1402Q	0.4028	72.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.P1402Q (Missense)		HNSC_MUSE	TCGA-CV-6441-01A-11D-1683-08	TCGA-CV-6441-11A-01D-1683-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERCC2	Nonsense	p.S74*	0.2787	122.0	0.0	0.0		Investigate Actionability	Cisplatin	Platinum-based chemotherapy	Chemotherapy	Somatic mutations that occured in ERCC2 were enriched in responders relative to nonresponsers in a cohort of patients with muscle-invasive urothelial carcinoma who received neoadjuvant cisplatin-based chemotherapy followed by cystectomy.	Liu D, Plimack ER, Hoffman-censits J, et al. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016;2(8):1094-6.	https://doi.org/10.1001/jamaoncol.2016.1056																	ERCC2 p.S74* (Nonsense)	0	HNSC_MUSE	TCGA-CV-5441-01A-01D-1512-08	TCGA-CV-5441-11A-01D-1512-08
Investigate Actionability	Clinical evidence			Somatic Variant	ARAF	Splice Site	p.X517_splice	0.3636	11.0	0.0	0.0		Investigate Actionability	Sorafenib	RAF inhibition	Targeted therapy	Activating mutations in ARAF may predict sensitivity to sorafenib or other RAF inhibitors. Patient received 5 year response to sorafenib with ARAF S214C.	Imielinski M, Greulich H, Kaplan B, et al. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J Clin Invest. 2014;124(4):1582-6.	https://doi.org/10.1172/JCI72763																	ARAF p.X517_splice (Splice Site)	0	HNSC_MUSE	TCGA-D6-A6EK-01A-11D-A31L-08	TCGA-D6-A6EK-10A-01D-A31J-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.E455A	0.2338	231.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.E455A (Missense)		HNSC_MUSE	TCGA-UF-A718-01A-22D-A34J-08	TCGA-UF-A718-10A-01D-A34M-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.L68F	0.2375	80.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.L68F (Missense)		HNSC_MUSE	TCGA-D6-8568-01A-11D-2394-08	TCGA-D6-8568-10A-01D-2394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.R382C	0.1739	69.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.R382C (Missense)		HNSC_MUSE	TCGA-CV-5970-01A-11D-1683-08	TCGA-CV-5970-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.R760H	0.1351	148.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.R760H (Missense)		HNSC_MUSE	TCGA-CN-4728-01A-01D-1434-08	TCGA-CN-4728-10A-01D-1434-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S605F	0.4516	31.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S605F (Missense)		HNSC_MUSE	TCGA-H7-A6C5-01A-11D-A30E-08	TCGA-H7-A6C5-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.S142L	0.1306	490.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.S142L (Missense)		HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	ERRFI1	Missense	p.Q350E	0.1023	264.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	Rapid disease regression was notd in a patient with a ERFFI1 p.E384X nonsense variant when treated with erlotinib.	Borad MJ, Champion MD, Egan JB, et al. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014;10(2):e1004135.	https://doi.org/10.1371/journal.pgen.1004135																	ERRFI1 p.Q350E (Missense)	0	HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.S343L	0.208	226.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.S343L (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.N528I	0.383	94.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.N528I (Missense)		HNSC_MUSE	TCGA-CN-5365-01A-01D-1434-08	TCGA-CN-5365-10A-01D-1434-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.A107T	0.2826	92.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.A107T (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.R554H	0.3288	146.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.R554H (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.N369S	0.2	60.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.N369S (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH6	Missense	p.S314R	0.2733	333.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH6 p.S314R (Missense)		HNSC_MUSE	TCGA-F7-A622-01A-11D-A28R-08	TCGA-F7-A622-10A-01D-A28U-08
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.G162V	0.2196	387.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MSH2 p.G162V (Missense)		HNSC_MUSE	TCGA-CN-A6V3-01A-12D-A34J-08	TCGA-CN-A6V3-10A-01D-A34M-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.V1222L	0.2756	127.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.V1222L (Missense)		HNSC_MUSE	TCGA-BA-4076-01A-01D-1434-08	TCGA-BA-4076-10A-01D-1434-08
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.L343P	0.2738	168.0	0.0	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344																	FLCN p.L343P (Missense)		HNSC_MUSE	TCGA-BA-4076-01A-01D-1434-08	TCGA-BA-4076-10A-01D-1434-08
Investigate Actionability	Clinical evidence			Somatic Variant	PBRM1	Missense	p.E105Q	0.1875	48.0	0.0	0.0		Investigate Actionability	Nivolumab	PD-1/PD-L1 inhibition	Immunotherapy	Clinical benefit from nivolumab in clear cell renal cell carcinoma patients was associated with loss-of-function mutations in PBRM1	Miao D, Margolis CA, Gao W, et al. Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science. 2018;359(6377):801-806.	https://doi.org/10.1126/science.aan5951																	PBRM1 p.E105Q (Missense)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability	Clinical evidence			Somatic Variant	MLH3	Missense	p.C501R	0.1	110.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596																	MLH3 p.C501R (Missense)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.C136R	0.3091	165.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.C136R (Missense)	1	HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R14S	0.5106	141.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R14S (Missense)	1	HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.H93R	0.243	107.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.H93R (Missense)	1	HNSC_MUSE	TCGA-CR-7369-01A-11D-2129-08	TCGA-CR-7369-10A-01D-2129-08
Investigate Actionability	Preclinical	Clinical evidence	Clinical trial	Somatic Variant	PTEN	Missense	p.R130Q	0.8552	145.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001	Investigate Actionability	0	Median PFS was longer in patients with normal PTEN, TP53, and PIK3CA status.	Hussain M, Daignault-newton S, Twardowski PW, et al. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol. 2018;36(10):991-999.	https://doi.org/10.1200/JCO.2017.75.7310					PTEN p.R130Q (Missense)	1	HNSC_MUSE	TCGA-BB-A6UM-01A-12D-A34J-08	TCGA-BB-A6UM-10A-01D-A34M-08
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Nonsense	p.Q39*	0.2105	19.0	0.0	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846										ALK p.Q39* (Nonsense)		HNSC_MUSE	TCGA-CQ-6221-01A-11D-2078-08	TCGA-CQ-6221-10A-01D-2078-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P849S	0.2576	66.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P849S (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Splice Site	p.X1124_splice	0.2143	70.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.X1124_splice (Splice Site)		HNSC_MUSE	TCGA-BA-6872-01A-11D-1870-08	TCGA-BA-6872-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.A2065V	0.3803	305.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.A2065V (Missense)		HNSC_MUSE	TCGA-BB-7870-01A-11D-2229-08	TCGA-BB-7870-10A-01D-2229-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1583S	0.3731	134.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1583S (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P1484L	0.2913	103.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P1484L (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.R1262C	0.1	60.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.R1262C (Missense)		HNSC_MUSE	TCGA-HD-8635-01A-11D-2394-08	TCGA-HD-8635-10A-01D-2394-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	JAK1	Nonsense	p.W1047*	0.75	24.0	0.0	0.0		Investigate Actionability	PU-H71	HSP90 inhibition	Targeted therapy	MOHITO JAK1 V658F transplated mice were highly sensitive to growth inhibition by PU-H71.	Kucine N, Marubayashi S, Bhagwat N, et al. Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. Blood. 2015;126(22):2479-83.	https://doi.org/10.1182/blood-2015-03-635821								Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK1 p.W1047* (Nonsense)		HNSC_MUSE	TCGA-CV-6962-01A-11D-1912-08	TCGA-CV-6962-10A-01D-1912-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.Q802P	0.1441	111.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.Q802P (Missense)		HNSC_MUSE	TCGA-DQ-5630-01A-01D-1870-08	TCGA-DQ-5630-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P570T	0.3092	401.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P570T (Missense)		HNSC_MUSE	TCGA-D6-A6ES-01A-12D-A31L-08	TCGA-D6-A6ES-10A-01D-A31J-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.G864V	0.5152	33.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.G864V (Missense)		HNSC_MUSE	TCGA-CV-7430-01A-11D-2129-08	TCGA-CV-7430-10A-01D-2129-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P452S	0.2099	181.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P452S (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	Preclinical		Clinical evidence	Somatic Variant	ARID1A	Missense	p.P452L	0.2077	183.0	0.0	0.0		Investigate Actionability	Durvalumab	PD-1/PD-L1 inhibition	Immunotherapy	Loss of function ARID1A mutations may predict sensitivity to immune checkpoint blockade, particularly PD-L1 inhibition. Anti-PD-L1 antibody reduced tumor mutational burden and prolonged survival of mice ARID1A-deficient but not ARID1A-wild-type ovarian tumors.	Shen J, Ju Z, Zhao W, et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018;24(5):556-562.	https://doi.org/10.1038/s41591-018-0012-z								Investigate Actionability	0	ARID1A mutations were associated with poorer prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					ARID1A p.P452L (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.S546*	0.375	120.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.S546* (Nonsense)		HNSC_MUSE	TCGA-UF-A7J9-01A-12D-A34J-08	TCGA-UF-A7J9-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.D1020N	0.3778	45.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.D1020N (Missense)		HNSC_MUSE	TCGA-CV-7406-01A-11D-2078-08	TCGA-CV-7406-10A-01D-2078-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1125S	0.3179	151.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1125S (Missense)		HNSC_MUSE	TCGA-CV-7254-01A-11D-2012-08	TCGA-CV-7254-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S140Y	0.5965	57.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S140Y (Missense)		HNSC_MUSE	TCGA-CV-7253-01A-11D-2012-08	TCGA-CV-7253-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1189Q	0.375	120.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1189Q (Missense)		HNSC_MUSE	TCGA-HD-A633-01A-11D-A28R-08	TCGA-HD-A633-10A-01D-A28U-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.Y1220C	0.1429	182.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.Y1220C (Missense)		HNSC_MUSE	TCGA-CN-5356-01A-01D-1434-08	TCGA-CN-5356-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.P913L	0.2105	57.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.P913L (Missense)		HNSC_MUSE	TCGA-CR-7373-01A-11D-2012-08	TCGA-CR-7373-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.A503E	0.3429	35.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.A503E (Missense)		HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G1162C	0.4286	14.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G1162C (Missense)		HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.Q1195K	0.1911	157.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.Q1195K (Missense)		HNSC_MUSE	TCGA-CN-4727-01A-01D-1434-08	TCGA-CN-4727-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.N442K	0.25	32.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.N442K (Missense)	0	HNSC_MUSE	TCGA-DQ-7588-01A-11D-2078-08	TCGA-DQ-7588-10B-01D-2078-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R393*	0.6494	154.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R393* (Nonsense)		HNSC_MUSE	TCGA-CN-4730-01A-01D-1434-08	TCGA-CN-4730-10A-01D-1434-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.L918R	0.1818	44.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.L918R (Missense)		HNSC_MUSE	TCGA-CV-A45W-01A-11D-A25D-08	TCGA-CV-A45W-10A-01D-A25E-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.G637R	0.2614	176.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.G637R (Missense)		HNSC_MUSE	TCGA-UF-A718-01A-22D-A34J-08	TCGA-UF-A718-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.A830T	0.3279	61.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.A830T (Missense)	0	HNSC_MUSE	TCGA-CV-6948-01A-11D-1912-08	TCGA-CV-6948-10A-01D-1912-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R479*	0.2889	90.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R479* (Nonsense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1300D	0.2403	129.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1300D (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E1311K	0.202	99.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E1311K (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1422F	0.5882	34.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1422F (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Preclinical			Somatic Variant	JAK3	Nonsense	p.W458*	0.2308	13.0	0.0	0.0		Investigate Actionability	Ruxolitinib	JAK inhibition	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687																	JAK3 p.W458* (Nonsense)	0	HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R448H	0.1304	46.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R448H (Missense)		HNSC_MUSE	TCGA-IQ-A61H-01A-11D-A30E-08	TCGA-IQ-A61H-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.T413A	0.1739	23.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.T413A (Missense)	0	HNSC_MUSE	TCGA-HD-8635-01A-11D-2394-08	TCGA-HD-8635-10A-01D-2394-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R979Q	0.28	50.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R979Q (Missense)		HNSC_MUSE	TCGA-CR-7383-01A-11D-2129-08	TCGA-CR-7383-10A-01D-2129-08
Investigate Actionability	Preclinical			Somatic Variant	MAPK1	Nonsense	p.E322*	0.3711	97.0	0.0	0.0		Investigate Actionability	Erlotinib	EGFR inhibition	Targeted therapy	In an exceptional responder, erlotinib resulted in complete and rapid response in MAPK1 mutant HNSCC	Balbach ST, Orkin SH. An Achilles' Heel for MLL-Rearranged Leukemias: Writers and Readers of H3 Lysine 36 Dimethylation. Cancer Discov. 2016;6(7):700-2.	https://doi.org/10.1001/jamaoncol.2015.34																	MAPK1 p.E322* (Nonsense)	0	HNSC_MUSE	TCGA-CV-7261-01A-11D-2012-08	TCGA-CV-7261-10A-01D-2013-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R1135Q	0.36	25.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R1135Q (Missense)		HNSC_MUSE	TCGA-CN-A63V-01A-11D-A28R-08	TCGA-CN-A63V-10A-01D-A28U-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.R539C	0.2618	191.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.R539C (Missense)		HNSC_MUSE	TCGA-WA-A7GZ-01A-11D-A34J-08	TCGA-WA-A7GZ-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Nonsense	p.R658*	0.1883	154.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.R658* (Nonsense)		HNSC_MUSE	TCGA-MT-A67A-01A-11D-A30E-08	TCGA-MT-A67A-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.H359D	0.0887	203.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.H359D (Missense)	0	HNSC_MUSE	TCGA-F7-A50G-01A-11D-A25Y-08	TCGA-F7-A50G-10A-01D-A25Y-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.E384K	0.1053	190.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.E384K (Missense)		HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.H884R	0.18	50.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.H884R (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.E567D	0.1458	144.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.E567D (Missense)	0	HNSC_MUSE	TCGA-CR-6487-01A-11D-1870-08	TCGA-CR-6487-10A-01D-1870-08
Investigate Actionability	Preclinical			Somatic Variant	FBXW7	Splice Site	p.X168_splice	0.2558	43.0	0.0	0.0		Investigate Actionability	Sirolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Breast cancer tumor cell lines harboring deletions or mutations in FBXW7 are particularly sensitive to rapamycin treatment, FBXW7 may be a biomarker for human cancers susceptible to treatment with inhibitors of the mTOR pathway.	Mao JH, Kim IJ, Wu D, et al. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science. 2008;321(5895):1499-502.	https://doi.org/10.1126/science.1162981																	FBXW7 p.X168_splice (Splice Site)		HNSC_MUSE	TCGA-P3-A6T7-01A-11D-A34J-08	TCGA-P3-A6T7-10A-01D-A34M-08
Investigate Actionability	Preclinical			Somatic Variant	SMARCA4	Missense	p.S1410L	0.6154	195.0	0.0	0.0		Investigate Actionability	VX-680	Aurora kinase inhibition	Targeted therapy	SMARCA4 inactivating mutations and sensitivity to AURKA inhibitor in preclinical models of non small cell lung adenocarcinoma	Tagal V, Wei S, Zhang W, et al. SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers. Nat Commun. 2017;8:14098.	https://doi.org/10.1038/ncomms14098																	SMARCA4 p.S1410L (Missense)		HNSC_MUSE	TCGA-CQ-5326-01A-01D-1870-08	TCGA-CQ-5326-10A-01D-1870-08
Investigate Actionability	Preclinical			Somatic Variant	PIK3CB	Missense	p.D1067V	0.3661	112.0	0.0	0.0		Investigate Actionability	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PIK3CB mutations may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p																	PIK3CB p.D1067V (Missense)	0	HNSC_MUSE	TCGA-CV-7421-01A-11D-2078-08	TCGA-CV-7421-10A-01D-2078-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X21_splice	0.2984	124.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X21_splice (Splice Site)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Nonsense	p.E1376*	0.1429	63.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.E1376* (Nonsense)		HNSC_MUSE	TCGA-CV-7407-01A-11D-2078-08	TCGA-CV-7407-10A-01D-2078-08
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLE	Splice Site	p.X823_splice	0.2881	59.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75					POLE p.X823_splice (Splice Site)		HNSC_MUSE	TCGA-CN-5360-01A-01D-1434-08	TCGA-CN-5360-10A-01D-1434-08
Investigate Actionability		Guideline		Somatic Variant	ABL1	Nonsense	p.E197*	0.3964	111.0	0.0	0.0									Investigate Actionability	Dasatinib	BCR-ABL inhibition	Targeted therapy	Selection of alternate TKI in the context of TKI-resistant or possible-TKI resistant BCR-ABL1 mutant CML may be based on mutantion profile.	National Comprehensive Cancer Network. Chronic Myeloid Leukemia NCCN Evidence Blocks (Version 1.2019). https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf. Accessed August 9th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf										ABL1 p.E197* (Nonsense)		HNSC_MUSE	TCGA-CN-A6V3-01A-12D-A34J-08	TCGA-CN-A6V3-10A-01D-A34M-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.L370F	0.2418	91.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.L370F (Missense)		HNSC_MUSE	TCGA-BB-A5HY-01A-11D-A28R-08	TCGA-BB-A5HY-10A-01D-A28U-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.S317I	0.2329	73.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.S317I (Missense)		HNSC_MUSE	TCGA-CV-A45Q-01A-11D-A24D-08	TCGA-CV-A45Q-10A-01D-A24F-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.Y197C	0.0709	127.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.Y197C (Missense)		HNSC_MUSE	TCGA-CN-5358-01A-01D-1512-08	TCGA-CN-5358-10A-01D-1512-08
Investigate Actionability		Clinical evidence		Somatic Variant	ESR1	Missense	p.V187L	0.3429	70.0	0.0	0.0									Investigate Actionability	Letrozole + Tamoxifen	Aromatase inhibition + ER signaling inhibition	Combination therapy	Nonsynonymous mutations in ESR1 were found in metastatic breast cancer patients that developed resistance to endrocrin therapy. These patients were treated with anti-estrogens (taxmoxifen and/or fulvestrant) and aromataste inhibitors (letrozole, anastrozole, and/or exemestane).	Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-51.	https://doi.org/10.1038/ng.2823										ESR1 p.V187L (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.H557R	0.4046	131.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405										BCR p.H557R (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.G81C	0.4167	132.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.G81C (Missense)		HNSC_MUSE	TCGA-CV-7429-01A-11D-2129-08	TCGA-CV-7429-10A-01D-2129-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79Q	0.352	125.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79Q (Missense)		HNSC_MUSE	TCGA-CV-6940-01A-11D-1912-08	TCGA-CV-6940-10A-01D-1912-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.V32G	0.1333	45.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.V32G (Missense)		HNSC_MUSE	TCGA-CN-6019-01A-11D-1683-08	TCGA-CN-6019-10A-01D-1683-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.0909	66.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		HNSC_MUSE	TCGA-CV-7424-01A-11D-2078-08	TCGA-CV-7424-10A-01D-2078-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E82V	0.6667	123.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E82V (Missense)		HNSC_MUSE	TCGA-T3-A92N-01A-11D-A391-08	TCGA-T3-A92N-10A-01D-A394-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79K	0.1096	73.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79K (Missense)		HNSC_MUSE	TCGA-CV-7099-01A-41D-2012-08	TCGA-CV-7099-10A-01D-2013-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79K	0.1014	69.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79K (Missense)		HNSC_MUSE	TCGA-P3-A5QF-01A-11D-A28R-08	TCGA-P3-A5QF-10A-01D-A28U-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L30F	0.2353	34.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30F (Missense)		HNSC_MUSE	TCGA-H7-7774-01A-21D-2078-08	TCGA-H7-7774-10A-01D-2078-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L562F	0.4068	118.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L562F (Missense)		HNSC_MUSE	TCGA-D6-A6EK-01A-11D-A31L-08	TCGA-D6-A6EK-10A-01D-A31J-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34P	0.3208	106.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34P (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.W24R	0.7358	53.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.W24R (Missense)		HNSC_MUSE	TCGA-CQ-A4CG-01A-11D-A25Y-08	TCGA-CQ-A4CG-10A-01D-A25Y-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L30H	0.5526	38.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30H (Missense)		HNSC_MUSE	TCGA-CQ-5324-01A-01D-1683-08	TCGA-CQ-5324-10A-01D-1683-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D457G	0.2462	260.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D457G (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29Y	0.2174	46.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29Y (Missense)		HNSC_MUSE	TCGA-IQ-A61H-01A-11D-A30E-08	TCGA-IQ-A61H-10A-01D-A30H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R34G	0.3333	117.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R34G (Missense)		HNSC_MUSE	TCGA-CR-7383-01A-11D-2129-08	TCGA-CR-7383-10A-01D-2129-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D262E	0.193	57.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D262E (Missense)		HNSC_MUSE	TCGA-BA-7269-01A-11D-2012-08	TCGA-BA-7269-10A-01D-2013-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.L30P	0.2647	34.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.L30P (Missense)		HNSC_MUSE	TCGA-MT-A67A-01A-11D-A30E-08	TCGA-MT-A67A-10A-01D-A30H-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.R456T	0.1048	105.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.R456T (Missense)		HNSC_MUSE	TCGA-HD-A6HZ-01A-12D-A31L-08	TCGA-HD-A6HZ-10A-01D-A31J-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.2427	103.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		HNSC_MUSE	TCGA-P3-A6T4-01A-11D-A34J-08	TCGA-P3-A6T4-10A-01D-A34M-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.I28T	0.5641	39.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.I28T (Missense)		HNSC_MUSE	TCGA-CV-7437-01A-21D-2129-08	TCGA-CV-7437-10A-01D-2129-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D29H	0.1915	47.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D29H (Missense)		HNSC_MUSE	TCGA-CV-6951-01A-11D-1912-08	TCGA-CV-6951-10A-01D-1912-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.T80A	0.0975	318.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.T80A (Missense)		HNSC_MUSE	TCGA-UF-A71B-01A-12D-A34J-08	TCGA-UF-A71B-10B-01D-A34M-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.D570N	0.1481	135.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.D570N (Missense)		HNSC_MUSE	TCGA-CV-6942-01A-21D-2012-08	TCGA-CV-6942-10A-01D-2013-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.W24C	0.4524	42.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.W24C (Missense)		HNSC_MUSE	TCGA-CV-6935-01A-11D-1912-08	TCGA-CV-6935-10A-01D-1912-08
Investigate Actionability		Preclinical		Somatic Variant	NFE2L2	Missense	p.E79Q	0.3239	71.0	0.0	0.0									Investigate Actionability	Radiation therapy	Radiation	Radiation therapy	In a study of survival after radiation in lung squamous cancer cell lines, NFE2L2 conferred radiation resistance.	Abazeed ME, Adams DJ, Hurov KE, et al. Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer Cancer Research. 2013; 73(20):6289-6298.	https://doi.org/10.1158/0008-5472.can-13-1616										NFE2L2 p.E79Q (Missense)		HNSC_MUSE	TCGA-CV-7177-01A-11D-2012-08	TCGA-CV-7177-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P2137A	0.263	308.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P2137A (Missense)		HNSC_MUSE	TCGA-CQ-7072-01A-21D-A30E-08	TCGA-CQ-7072-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Q143P	0.25	48.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Q143P (Missense)		HNSC_MUSE	TCGA-CQ-7072-01A-21D-A30E-08	TCGA-CQ-7072-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.H15N	0.4062	32.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.H15N (Missense)		HNSC_MUSE	TCGA-CV-7097-01A-11D-2012-08	TCGA-CV-7097-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	ZRSR2	Missense	p.R378Q	0.4091	110.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ZRSR2 p.R378Q (Missense)		HNSC_MUSE	TCGA-UF-A7JC-01A-21D-A34J-08	TCGA-UF-A7JC-10A-01D-A34M-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.K536N	0.1132	53.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.K536N (Missense)		HNSC_MUSE	TCGA-CV-7099-01A-41D-2012-08	TCGA-CV-7099-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.E986Q	0.3158	57.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.E986Q (Missense)		HNSC_MUSE	TCGA-HD-A633-01A-11D-A28R-08	TCGA-HD-A633-10A-01D-A28U-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R71Q	0.2792	265.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R71Q (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.R1016K	0.4308	65.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.R1016K (Missense)		HNSC_MUSE	TCGA-CN-4727-01A-01D-1434-08	TCGA-CN-4727-10A-01D-1434-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.G542W	0.1452	62.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.G542W (Missense)		HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L1000F	0.3796	108.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L1000F (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.K888R	0.1756	205.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.K888R (Missense)		HNSC_MUSE	TCGA-CV-7433-01A-11D-2129-08	TCGA-CV-7433-10A-01D-2129-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.Q1169H	0.3299	97.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.Q1169H (Missense)		HNSC_MUSE	TCGA-BA-6869-01A-11D-1870-08	TCGA-BA-6869-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.S1391C	0.1986	141.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.S1391C (Missense)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.E444K	0.1692	195.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.E444K (Missense)		HNSC_MUSE	TCGA-CR-6481-01A-11D-1870-08	TCGA-CR-6481-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R191Q	0.1381	485.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R191Q (Missense)		HNSC_MUSE	TCGA-CV-7247-01A-11D-2012-08	TCGA-CV-7247-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.E22K	0.0947	95.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.E22K (Missense)		HNSC_MUSE	TCGA-MT-A67F-01A-11D-A30E-08	TCGA-MT-A67F-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R881T	0.4162	173.0	0.0	0.0																Investigate Actionability	0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ASXL1 p.R881T (Missense)		HNSC_MUSE	TCGA-D6-A6ES-01A-12D-A31L-08	TCGA-D6-A6ES-10A-01D-A31J-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.D1650Y	0.1011	89.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.D1650Y (Missense)		HNSC_MUSE	TCGA-CV-6955-01A-11D-2012-08	TCGA-CV-6955-10A-01D-2013-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.P317S	0.165	309.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.P317S (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	STAG2	Missense	p.L742I	0.1149	148.0	0.0	0.0																Investigate Actionability	0	NCCN guideline for Myelodysplastic Syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					STAG2 p.L742I (Missense)		HNSC_MUSE	TCGA-BA-6870-01A-11D-1870-08	TCGA-BA-6870-10A-01D-1870-08
Investigate Actionability			Guideline	Somatic Variant	PRPF8	Missense	p.R642C	0.3698	192.0	0.0	0.0																Investigate Actionability	0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					PRPF8 p.R642C (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability			Guideline	Somatic Variant	ETV6	Missense	p.R217T	0.1591	132.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					ETV6 p.R217T (Missense)		HNSC_MUSE	TCGA-CV-6436-01A-11D-1683-08	TCGA-CV-6436-11A-01D-1683-08
Investigate Actionability			Guideline	Somatic Variant	RUNX1	Missense	p.Q235E	0.2178	101.0	0.0	0.0																Investigate Actionability	0	May be familial in rare cases.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf					RUNX1 p.Q235E (Missense)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.R90*	0.0725	193.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R90* (Nonsense)		HNSC_MUSE	TCGA-P3-A6SW-01A-11D-A34J-08	TCGA-P3-A6SW-10A-01D-A34M-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Nonsense	p.Q169*	0.137	73.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.Q169* (Nonsense)		HNSC_MUSE	TCGA-CV-A463-01A-11D-A25Y-08	TCGA-CV-A463-10A-01D-A25Y-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.V188I	0.197	66.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.V188I (Missense)		HNSC_MUSE	TCGA-T3-A92N-01A-11D-A391-08	TCGA-T3-A92N-10A-01D-A394-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.P715L	0.4857	70.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.P715L (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Investigate Actionability			Clinical evidence	Somatic Variant	JAK2	Splice Site	p.X405_splice	0.6471	17.0	0.0	0.0																Investigate Actionability	0	A study of target-specific sequencing data taken from 112 ALL patients showed an association between JAK1 or JAK2 mutation and decreased survival.	Feng J, Li Y, Jia Y, et al. Spectrum of somatic mutations detected by targeted next-generation sequencing and their prognostic significance in adult patients with acute lymphoblastic leukemia. J Hematol Oncol. 2017;10(1):61.	https://doi.org/10.1186/s13045-017-0431-1					JAK2 p.X405_splice (Splice Site)		HNSC_MUSE	TCGA-HD-7754-01A-11D-2078-08	TCGA-HD-7754-10A-01D-2078-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.G34E	0.3158	38.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.G34E (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.R474*	0.4	200.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R474* (Nonsense)		HNSC_MUSE	TCGA-BB-4224-01A-01D-1434-08	TCGA-BB-4224-10A-01D-1434-08
Investigate Actionability			Clinical evidence	Somatic Variant	RBM10	Missense	p.R792W	0.2	35.0	0.0	0.0																Investigate Actionability	1	RBM10 mutations were associated with better prognosis in a study of 109 microdissected pancreatic adenocarcinoma tumors. Note that all RBM10-mutant patients were found to have high-grade pT3 stage tumors.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744					RBM10 p.R792W (Missense)		HNSC_MUSE	TCGA-CN-4733-01A-02D-1870-08	TCGA-CN-4733-10A-01D-1870-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Missense	p.R151C	0.2083	96.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R151C (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.R431K	0.1608	199.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.R431K (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Investigate Actionability			Clinical evidence	Somatic Variant	MC1R	Missense	p.A164T	0.3438	96.0	0.0	0.0																Investigate Actionability	0	The presence of MC1R polymorphisms in a cohort of 53 metastatic melanoma patients treated with BRAF inhibitors was associated with a poorer prognosis (ORR: 59% vs. 95%; PFS shorter than 6 months: 72% vs. 33%).	Guida M, Strippoli S, Ferretta A, et al. Detrimental effects of Melanocortin-1 receptor (MC1R) polymorphisms on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. Pigment Cell Melanoma Res. 2016;	https://doi.org/10.1111/pcmr.12516					MC1R p.A164T (Missense)		HNSC_MUSE	TCGA-D6-A74Q-01A-11D-A34J-08	TCGA-D6-A74Q-10A-02D-A34M-08
Investigate Actionability			Clinical evidence	Somatic Variant	CTNNB1	Nonsense	p.R535*	0.1263	95.0	0.0	0.0																Investigate Actionability	1	Tumors harboring mutations in the WNT pathway, such as CTNNB1, have extremely good prognosis.	Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma Comprises Four Distinct Molecular Variants JCO. 2011; 29(11):1408-1414.	https://doi.org/10.1200/JCO.2009.27.4324					CTNNB1 p.R535* (Nonsense)		HNSC_MUSE	TCGA-CV-6938-01A-11D-1912-08	TCGA-CV-6938-10A-01D-1912-08
Investigate Actionability			Clinical evidence	Somatic Variant	BLM	Missense	p.E674Q	0.2411	141.0	0.0	0.0																Investigate Actionability	0	BLM may indicate a predisposition for early onset of colorectal cancer, although with a low-moderate penetrance.	De voer RM, Hahn MM, Mensenkamp AR, et al. Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Sci Rep. 2015;5:14060.	https://doi.org/10.1038/srep14060					BLM p.E674Q (Missense)		HNSC_MUSE	TCGA-CQ-7069-01A-11D-2394-08	TCGA-CQ-7069-10A-01D-2394-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.G18R	0.3466	502.0	0.0	0.0																									MDM2 p.G18R (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.S293T	0.413	46.0	0.0	0.0																									EWSR1 p.S293T (Missense)		HNSC_MUSE	TCGA-CR-7402-01A-11D-2012-08	TCGA-CR-7402-10A-01D-2013-08
Biologically Relevant				Somatic Variant	FIP1L1	Missense	p.D174N	0.2381	63.0	0.0	0.0																									FIP1L1 p.D174N (Missense)		HNSC_MUSE	TCGA-IQ-A61I-01A-11D-A30E-08	TCGA-IQ-A61I-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.D434H	0.3231	65.0	0.0	0.0																									EWSR1 p.D434H (Missense)		HNSC_MUSE	TCGA-IQ-A61I-01A-11D-A30E-08	TCGA-IQ-A61I-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.D282H	0.6667	15.0	0.0	0.0																									CCND1 p.D282H (Missense)		HNSC_MUSE	TCGA-CV-6441-01A-11D-1683-08	TCGA-CV-6441-11A-01D-1683-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.I262M	0.2632	38.0	0.0	0.0																									MLH1 p.I262M (Missense)		HNSC_MUSE	TCGA-CV-7425-01A-11D-2078-08	TCGA-CV-7425-10A-01D-2078-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E88*	0.4583	48.0	0.0	0.0																									CDKN2A p.E88* (Nonsense)		HNSC_MUSE	TCGA-BA-A4IF-01A-11D-A25Y-08	TCGA-BA-A4IF-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.G353C	0.3276	58.0	0.0	0.0																									FLI1 p.G353C (Missense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.Y525C	0.2407	54.0	0.0	0.0																									KEAP1 p.Y525C (Missense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	KEAP1	Nonsense	p.E134*	0.2281	57.0	0.0	0.0																									KEAP1 p.E134* (Nonsense)		HNSC_MUSE	TCGA-UF-A7JF-01A-11D-A34J-08	TCGA-UF-A7JF-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E817K	0.1892	148.0	0.0	0.0																									ROS1 p.E817K (Missense)		HNSC_MUSE	TCGA-QK-A6IG-01A-11D-A31L-08	TCGA-QK-A6IG-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6389	36.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-QK-A6IG-01A-11D-A31L-08	TCGA-QK-A6IG-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.P156H	0.2529	87.0	0.0	0.0																									EPCAM p.P156H (Missense)		HNSC_MUSE	TCGA-CN-5359-01A-01D-1434-08	TCGA-CN-5359-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.425	40.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CN-5359-01A-01D-1434-08	TCGA-CN-5359-10A-01D-1434-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R272C	0.1278	133.0	0.0	0.0																									KEAP1 p.R272C (Missense)		HNSC_MUSE	TCGA-CN-5359-01A-01D-1434-08	TCGA-CN-5359-10A-01D-1434-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R470C	0.5714	35.0	0.0	0.0																									KEAP1 p.R470C (Missense)		HNSC_MUSE	TCGA-CV-5434-01A-01D-1683-08	TCGA-CV-5434-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.A68P	0.3	20.0	0.0	0.0																									CDKN2A p.A68P (Missense)		HNSC_MUSE	TCGA-QK-A6II-01A-11D-A31L-08	TCGA-QK-A6II-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P2182S	0.2571	70.0	0.0	0.0																									ROS1 p.P2182S (Missense)		HNSC_MUSE	TCGA-F7-7848-01A-11D-2129-08	TCGA-F7-7848-10A-01D-2129-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.M367I	0.3862	145.0	0.0	0.0																									RUNX1T1 p.M367I (Missense)		HNSC_MUSE	TCGA-F7-7848-01A-11D-2129-08	TCGA-F7-7848-10A-01D-2129-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S103Y	0.3095	42.0	0.0	0.0																									KEAP1 p.S103Y (Missense)		HNSC_MUSE	TCGA-CN-6012-01A-11D-1683-08	TCGA-CN-6012-10A-01D-1683-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.5	16.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CV-7243-01A-11D-2012-08	TCGA-CV-7243-10A-01D-2013-08
Biologically Relevant				Somatic Variant	PMS2	Nonsense	p.R3*	0.4545	99.0	0.0	0.0																									PMS2 p.R3* (Nonsense)		HNSC_MUSE	TCGA-UP-A6WW-01A-12D-A34J-08	TCGA-UP-A6WW-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R473Q	0.45	60.0	0.0	0.0																									RUNX1T1 p.R473Q (Missense)		HNSC_MUSE	TCGA-BA-6868-01B-12D-1912-08	TCGA-BA-6868-10A-01D-1912-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S144F	0.1538	52.0	0.0	0.0																									NF1 p.S144F (Missense)		HNSC_MUSE	TCGA-CV-A45U-01A-12D-A24D-08	TCGA-CV-A45U-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R251*	0.3607	61.0	0.0	0.0																									RB1 p.R251* (Nonsense)		HNSC_MUSE	TCGA-KU-A6H7-01A-11D-A31L-08	TCGA-KU-A6H7-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.S489L	0.1414	99.0	0.0	0.0																									POT1 p.S489L (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.K348R	0.1282	39.0	0.0	0.0																									TPX2 p.K348R (Missense)		HNSC_MUSE	TCGA-CN-6992-01A-11D-1912-08	TCGA-CN-6992-10A-01D-1912-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.L481F	0.1667	42.0	0.0	0.0																									ESRP1 p.L481F (Missense)		HNSC_MUSE	TCGA-CV-6003-01A-11D-1683-08	TCGA-CV-6003-11A-01D-1683-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E120*	0.439	41.0	0.0	0.0																									CDKN2A p.E120* (Nonsense)		HNSC_MUSE	TCGA-CV-6003-01A-11D-1683-08	TCGA-CV-6003-11A-01D-1683-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.3793	29.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-6003-01A-11D-1683-08	TCGA-CV-6003-11A-01D-1683-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.P278L	0.5568	88.0	0.0	0.0																									KEAP1 p.P278L (Missense)		HNSC_MUSE	TCGA-UF-A71E-01A-31D-A34J-08	TCGA-UF-A71E-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.V1630I	0.1908	173.0	0.0	0.0																									MTOR p.V1630I (Missense)		HNSC_MUSE	TCGA-C9-A47Z-01A-11D-A24D-08	TCGA-C9-A47Z-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.1481	54.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-CV-5444-01A-02D-1512-08	TCGA-CV-5444-11A-01D-1512-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.E278K	0.0672	268.0	0.0	0.0																									CRKL p.E278K (Missense)		HNSC_MUSE	TCGA-CV-5444-01A-02D-1512-08	TCGA-CV-5444-11A-01D-1512-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.2222	45.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-QK-A64Z-01A-11D-A30E-08	TCGA-QK-A64Z-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.N227S	0.3451	113.0	0.0	0.0																									PAK1 p.N227S (Missense)		HNSC_MUSE	TCGA-CV-7422-01A-21D-2078-08	TCGA-CV-7422-10A-01D-2078-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.C319F	0.2456	57.0	0.0	0.0																									KEAP1 p.C319F (Missense)		HNSC_MUSE	TCGA-CV-7248-01A-11D-2012-08	TCGA-CV-7248-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.7273	44.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-BA-6873-01A-11D-1870-08	TCGA-BA-6873-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CRKL	Missense	p.I99M	0.6111	36.0	0.0	0.0																									CRKL p.I99M (Missense)		HNSC_MUSE	TCGA-CV-A6JE-01A-11D-A31L-08	TCGA-CV-A6JE-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.7031	64.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-7254-01A-11D-2012-08	TCGA-CV-7254-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Y705N	0.1858	183.0	0.0	0.0																									NTRK3 p.Y705N (Missense)		HNSC_MUSE	TCGA-CV-7254-01A-11D-2012-08	TCGA-CV-7254-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.3913	23.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CV-7424-01A-11D-2078-08	TCGA-CV-7424-10A-01D-2078-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.K504E	0.3134	67.0	0.0	0.0																									POT1 p.K504E (Missense)		HNSC_MUSE	TCGA-T3-A92N-01A-11D-A391-08	TCGA-T3-A92N-10A-01D-A394-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P564T	0.4902	51.0	0.0	0.0																									RUNX1T1 p.P564T (Missense)		HNSC_MUSE	TCGA-T3-A92N-01A-11D-A391-08	TCGA-T3-A92N-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D84G	0.3043	23.0	0.0	0.0																									CDKN2A p.D84G (Missense)		HNSC_MUSE	TCGA-CV-A6JM-01A-11D-A31L-08	TCGA-CV-A6JM-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	PAK1	Missense	p.L405I	0.7222	18.0	0.0	0.0																									PAK1 p.L405I (Missense)		HNSC_MUSE	TCGA-CV-A6JM-01A-11D-A31L-08	TCGA-CV-A6JM-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.G419R	0.1736	144.0	0.0	0.0																									TACC3 p.G419R (Missense)		HNSC_MUSE	TCGA-UF-A7JO-01A-11D-A34J-08	TCGA-UF-A7JO-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.2759	29.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-UF-A7JO-01A-11D-A34J-08	TCGA-UF-A7JO-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D74N	0.7222	18.0	0.0	0.0																									CDKN2A p.D74N (Missense)		HNSC_MUSE	TCGA-P3-A6T3-01A-11D-A34J-08	TCGA-P3-A6T3-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	PMS2	Splice Site	p.X55_splice	0.2966	118.0	0.0	0.0																									PMS2 p.X55_splice (Splice Site)		HNSC_MUSE	TCGA-BA-6871-01A-11D-1870-08	TCGA-BA-6871-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.5882	17.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		HNSC_MUSE	TCGA-BA-4075-01A-01D-1434-08	TCGA-BA-4075-10A-01D-1434-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.I446V	0.0704	142.0	0.0	0.0																									MDM2 p.I446V (Missense)		HNSC_MUSE	TCGA-BA-4075-01A-01D-1434-08	TCGA-BA-4075-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.Y129*	0.6216	37.0	0.0	0.0																									CDKN2A p.Y129* (Nonsense)		HNSC_MUSE	TCGA-BA-6872-01A-11D-1870-08	TCGA-BA-6872-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4783	46.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-A6JD-01A-11D-A31L-08	TCGA-CV-A6JD-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.D259G	0.1897	174.0	0.0	0.0																									NTRK2 p.D259G (Missense)		HNSC_MUSE	TCGA-CV-A6JD-01A-11D-A31L-08	TCGA-CV-A6JD-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.G2148V	0.2078	77.0	0.0	0.0																									ROS1 p.G2148V (Missense)		HNSC_MUSE	TCGA-CN-5364-01A-01D-1434-08	TCGA-CN-5364-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6471	17.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CR-5247-01A-01D-2012-08	TCGA-CR-5247-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.N42H	0.543	186.0	0.0	0.0																									CDKN2A p.N42H (Missense)		HNSC_MUSE	TCGA-CQ-6220-01A-11D-1912-08	TCGA-CQ-6220-10A-01D-1912-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.T587S	0.3043	23.0	0.0	0.0																									RUNX1T1 p.T587S (Missense)		HNSC_MUSE	TCGA-CN-A63T-01A-11D-A28R-08	TCGA-CN-A63T-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H412N	0.2358	229.0	0.0	0.0																									RUNX1T1 p.H412N (Missense)		HNSC_MUSE	TCGA-CN-A63T-01A-11D-A28R-08	TCGA-CN-A63T-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P204S	0.2388	67.0	0.0	0.0																									COL1A1 p.P204S (Missense)		HNSC_MUSE	TCGA-F7-A50I-01A-11D-A28R-08	TCGA-F7-A50I-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.I519M	0.1897	58.0	0.0	0.0																									KEAP1 p.I519M (Missense)		HNSC_MUSE	TCGA-HD-A633-01A-11D-A28R-08	TCGA-HD-A633-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.C23Y	0.4115	209.0	0.0	0.0																									KEAP1 p.C23Y (Missense)		HNSC_MUSE	TCGA-BB-7870-01A-11D-2229-08	TCGA-BB-7870-10A-01D-2229-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.T652K	0.1638	116.0	0.0	0.0																									EML4 p.T652K (Missense)		HNSC_MUSE	TCGA-D6-A6EK-01A-11D-A31L-08	TCGA-D6-A6EK-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.P183L	0.2341	205.0	0.0	0.0																									RUNX1T1 p.P183L (Missense)		HNSC_MUSE	TCGA-CN-5356-01A-01D-1434-08	TCGA-CN-5356-10A-01D-1434-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H632Y	0.2143	56.0	0.0	0.0																									NTRK3 p.H632Y (Missense)		HNSC_MUSE	TCGA-CN-5356-01A-01D-1434-08	TCGA-CN-5356-10A-01D-1434-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.R579*	0.3333	81.0	0.0	0.0																									RB1 p.R579* (Nonsense)		HNSC_MUSE	TCGA-QK-A6V9-01A-11D-A34J-08	TCGA-QK-A6V9-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.D412N	0.1852	135.0	0.0	0.0																									TACC3 p.D412N (Missense)		HNSC_MUSE	TCGA-CN-5374-01A-01D-1434-08	TCGA-CN-5374-10A-01D-1434-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.S418L	0.2735	117.0	0.0	0.0																									ESRP1 p.S418L (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.4286	21.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.D831N	0.2235	179.0	0.0	0.0																									COL1A1 p.D831N (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.D29H	0.2312	173.0	0.0	0.0																									KEAP1 p.D29H (Missense)		HNSC_MUSE	TCGA-CN-4723-01A-01D-1434-08	TCGA-CN-4723-10A-01D-1434-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S693N	0.3617	94.0	0.0	0.0																									ROS1 p.S693N (Missense)		HNSC_MUSE	TCGA-CQ-6221-01A-11D-2078-08	TCGA-CQ-6221-10A-01D-2078-08
Biologically Relevant				Somatic Variant	BRD4	Splice Site	p.X720_splice	0.3167	120.0	0.0	0.0																									BRD4 p.X720_splice (Splice Site)		HNSC_MUSE	TCGA-CQ-6221-01A-11D-2078-08	TCGA-CQ-6221-10A-01D-2078-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X565_splice	0.4194	31.0	0.0	0.0																									RB1 p.X565_splice (Splice Site)		HNSC_MUSE	TCGA-CR-7374-01A-11D-2012-08	TCGA-CR-7374-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.N420I	0.6194	268.0	0.0	0.0																									NF1 p.N420I (Missense)		HNSC_MUSE	TCGA-CR-7374-01A-11D-2012-08	TCGA-CR-7374-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.H729N	0.1316	38.0	0.0	0.0																									NTRK3 p.H729N (Missense)		HNSC_MUSE	TCGA-UF-A7JJ-01A-11D-A34J-08	TCGA-UF-A7JJ-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.P158S	0.1146	96.0	0.0	0.0																									POT1 p.P158S (Missense)		HNSC_MUSE	TCGA-CV-7089-01A-11D-2012-08	TCGA-CV-7089-10A-01D-2013-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.Q157H	0.1263	95.0	0.0	0.0																									POT1 p.Q157H (Missense)		HNSC_MUSE	TCGA-CV-7089-01A-11D-2012-08	TCGA-CV-7089-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.L1083F	0.1471	34.0	0.0	0.0																									NF1 p.L1083F (Missense)		HNSC_MUSE	TCGA-CR-7394-01A-11D-2012-08	TCGA-CR-7394-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.A269V	0.1818	110.0	0.0	0.0																									CDK4 p.A269V (Missense)		HNSC_MUSE	TCGA-CV-7250-01A-11D-2012-08	TCGA-CV-7250-10A-01D-2013-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S146L	0.4524	42.0	0.0	0.0																									MYC p.S146L (Missense)		HNSC_MUSE	TCGA-CV-A45V-01A-21D-A25D-08	TCGA-CV-A45V-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.T32S	0.1161	112.0	0.0	0.0																									RUNX1T1 p.T32S (Missense)		HNSC_MUSE	TCGA-CN-4727-01A-01D-1434-08	TCGA-CN-4727-10A-01D-1434-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.S45Y	0.1907	257.0	0.0	0.0																									KEAP1 p.S45Y (Missense)		HNSC_MUSE	TCGA-CN-4727-01A-01D-1434-08	TCGA-CN-4727-10A-01D-1434-08
Biologically Relevant				Somatic Variant	PDGFB	Missense	p.P91L	0.2432	37.0	0.0	0.0																									PDGFB p.P91L (Missense)		HNSC_MUSE	TCGA-BA-A6DF-01A-11D-A30E-08	TCGA-BA-A6DF-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.S1793*	0.25	40.0	0.0	0.0																									ROS1 p.S1793* (Nonsense)		HNSC_MUSE	TCGA-T2-A6X2-01A-12D-A34J-08	TCGA-T2-A6X2-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E5K	0.2102	176.0	0.0	0.0																									PMS2 p.E5K (Missense)		HNSC_MUSE	TCGA-T2-A6X2-01A-12D-A34J-08	TCGA-T2-A6X2-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.L2172M	0.4038	52.0	0.0	0.0																									MTOR p.L2172M (Missense)		HNSC_MUSE	TCGA-DQ-7588-01A-11D-2078-08	TCGA-DQ-7588-10B-01D-2078-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R470H	0.3947	38.0	0.0	0.0																									KEAP1 p.R470H (Missense)		HNSC_MUSE	TCGA-DQ-7588-01A-11D-2078-08	TCGA-DQ-7588-10B-01D-2078-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.L240V	0.1098	173.0	0.0	0.0																									TPX2 p.L240V (Missense)		HNSC_MUSE	TCGA-CN-4730-01A-01D-1434-08	TCGA-CN-4730-10A-01D-1434-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.E41V	0.2703	418.0	0.0	0.0																									PMS2 p.E41V (Missense)		HNSC_MUSE	TCGA-CQ-7071-01A-12D-A30E-08	TCGA-CQ-7071-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CD274	Missense	p.E71K	0.3288	73.0	0.0	0.0																									CD274 p.E71K (Missense)		HNSC_MUSE	TCGA-CQ-7071-01A-12D-A30E-08	TCGA-CQ-7071-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.M695I	0.2459	61.0	0.0	0.0																									RB1 p.M695I (Missense)		HNSC_MUSE	TCGA-CQ-7071-01A-12D-A30E-08	TCGA-CQ-7071-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.E2607K	0.3333	183.0	0.0	0.0																									NF1 p.E2607K (Missense)		HNSC_MUSE	TCGA-CQ-7071-01A-12D-A30E-08	TCGA-CQ-7071-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.L213F	0.2941	34.0	0.0	0.0																									CDK4 p.L213F (Missense)		HNSC_MUSE	TCGA-IQ-7630-01A-11D-2078-08	TCGA-IQ-7630-10A-01D-2078-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R112H	0.3438	32.0	0.0	0.0																									CDKN2A p.R112H (Missense)		HNSC_MUSE	TCGA-CV-A465-01A-11D-A25Y-08	TCGA-CV-A465-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.E450K	0.2835	127.0	0.0	0.0																									POT1 p.E450K (Missense)		HNSC_MUSE	TCGA-CR-6480-01A-11D-1870-08	TCGA-CR-6480-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.G310V	0.2286	35.0	0.0	0.0																									ESRP1 p.G310V (Missense)		HNSC_MUSE	TCGA-CV-7104-01A-11D-2012-08	TCGA-CV-7104-10A-01D-2013-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H488N	0.2933	75.0	0.0	0.0																									ROS1 p.H488N (Missense)		HNSC_MUSE	TCGA-CR-7364-01A-11D-2012-08	TCGA-CR-7364-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.T253N	0.1562	64.0	0.0	0.0																									NTRK3 p.T253N (Missense)		HNSC_MUSE	TCGA-CR-7364-01A-11D-2012-08	TCGA-CR-7364-10A-01D-2013-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.A241T	0.4516	93.0	0.0	0.0																									TPX2 p.A241T (Missense)		HNSC_MUSE	TCGA-CR-7364-01A-11D-2012-08	TCGA-CR-7364-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83Y	0.8125	48.0	0.0	0.0																									CDKN2A p.H83Y (Missense)		HNSC_MUSE	TCGA-CV-5440-01A-01D-1512-08	TCGA-CV-5440-11A-01D-1512-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.K389N	0.1723	412.0	0.0	0.0																									MYC p.K389N (Missense)		HNSC_MUSE	TCGA-CV-6948-01A-11D-1912-08	TCGA-CV-6948-10A-01D-1912-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.P138R	0.4048	42.0	0.0	0.0																									MLH1 p.P138R (Missense)		HNSC_MUSE	TCGA-CV-5432-01A-02D-1683-08	TCGA-CV-5432-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.375	16.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-5432-01A-02D-1683-08	TCGA-CV-5432-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5	24.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-6953-01A-11D-1912-08	TCGA-CV-6953-10A-01D-1912-08
Biologically Relevant				Somatic Variant	CDK4	Missense	p.G216E	0.1818	44.0	0.0	0.0																									CDK4 p.G216E (Missense)		HNSC_MUSE	TCGA-CV-6953-01A-11D-1912-08	TCGA-CV-6953-10A-01D-1912-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.L667M	0.4783	46.0	0.0	0.0																									PDGFRB p.L667M (Missense)		HNSC_MUSE	TCGA-CV-6956-01A-21D-2012-08	TCGA-CV-6956-10A-01D-2013-08
Biologically Relevant				Somatic Variant	NTRK1	Missense	p.K547T	0.1622	37.0	0.0	0.0																									NTRK1 p.K547T (Missense)		HNSC_MUSE	TCGA-CV-7434-01A-11D-2129-08	TCGA-CV-7434-10A-01D-2129-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I1848L	0.7973	74.0	0.0	0.0																									ROS1 p.I1848L (Missense)		HNSC_MUSE	TCGA-BB-A5HY-01A-11D-A28R-08	TCGA-BB-A5HY-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.Q1105R	0.3	70.0	0.0	0.0																									BRD4 p.Q1105R (Missense)		HNSC_MUSE	TCGA-BB-A5HY-01A-11D-A28R-08	TCGA-BB-A5HY-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.2564	39.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CR-7386-01A-11D-2012-08	TCGA-CR-7386-10A-01D-2013-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.I351T	0.1579	38.0	0.0	0.0																									POT1 p.I351T (Missense)		HNSC_MUSE	TCGA-CR-7399-01A-11D-2012-08	TCGA-CR-7399-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.5918	49.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-CR-6491-01A-11D-1870-08	TCGA-CR-6491-10A-01D-1870-08
Biologically Relevant				Somatic Variant	TACC3	Splice Site	p.X55_splice	0.1429	70.0	0.0	0.0																									TACC3 p.X55_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A45P-01A-11D-A24D-08	TCGA-CV-A45P-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4222	45.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-A45P-01A-11D-A24D-08	TCGA-CV-A45P-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	RAF1	Missense	p.E104K	0.3618	152.0	0.0	0.0																									RAF1 p.E104K (Missense)		HNSC_MUSE	TCGA-CR-7367-01A-11D-2012-08	TCGA-CR-7367-10A-01D-2013-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.H1418Y	0.1607	56.0	0.0	0.0																									COL1A1 p.H1418Y (Missense)		HNSC_MUSE	TCGA-CR-7367-01A-11D-2012-08	TCGA-CR-7367-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R488L	0.4561	57.0	0.0	0.0																									RUNX1T1 p.R488L (Missense)		HNSC_MUSE	TCGA-CQ-A4CI-01A-11D-A25Y-08	TCGA-CQ-A4CI-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	MTOR	Nonsense	p.E43*	0.1803	122.0	0.0	0.0																									MTOR p.E43* (Nonsense)		HNSC_MUSE	TCGA-CV-A45X-01A-21D-A25D-08	TCGA-CV-A45X-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	NTRK3	Nonsense	p.S77*	0.2333	90.0	0.0	0.0																									NTRK3 p.S77* (Nonsense)		HNSC_MUSE	TCGA-CQ-6218-01A-11D-1912-08	TCGA-CQ-6218-10A-01D-1912-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.A532S	0.2381	84.0	0.0	0.0																									RUNX1T1 p.A532S (Missense)		HNSC_MUSE	TCGA-BA-4074-01A-01D-1434-08	TCGA-BA-4074-10A-01D-1434-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.H967Y	0.3467	75.0	0.0	0.0																									MTOR p.H967Y (Missense)		HNSC_MUSE	TCGA-TN-A7HL-01A-11D-A34J-08	TCGA-TN-A7HL-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V1187A	0.1171	111.0	0.0	0.0																									ROS1 p.V1187A (Missense)		HNSC_MUSE	TCGA-CV-5430-01A-02D-1683-08	TCGA-CV-5430-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.7143	21.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-DQ-5629-01A-01D-1870-08	TCGA-DQ-5629-10A-01D-1870-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A735V	0.2596	104.0	0.0	0.0																									COL1A1 p.A735V (Missense)		HNSC_MUSE	TCGA-CV-7242-01A-11D-2012-08	TCGA-CV-7242-10A-01D-2013-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.P221S	0.619	105.0	0.0	0.0																									ROS1 p.P221S (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.E88K	0.7368	19.0	0.0	0.0																									CDKN2A p.E88K (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.G2262E	0.3524	210.0	0.0	0.0																									NF1 p.G2262E (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.D414N	0.3898	59.0	0.0	0.0																									BRD4 p.D414N (Missense)		HNSC_MUSE	TCGA-CV-7568-01A-11D-2229-08	TCGA-CV-7568-10A-01D-2229-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.3846	26.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CR-6492-01A-12D-2078-08	TCGA-CR-6492-10A-01D-2078-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.A310D	0.127	63.0	0.0	0.0																									TACC3 p.A310D (Missense)		HNSC_MUSE	TCGA-QK-A8ZB-01A-11D-A391-08	TCGA-QK-A8ZB-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.3095	42.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-QK-A8ZB-01A-11D-A391-08	TCGA-QK-A8ZB-10A-01D-A394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.8824	17.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CV-5977-01A-11D-1683-08	TCGA-CV-5977-11A-01D-1683-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.V392A	0.4737	76.0	0.0	0.0																									FGFR2 p.V392A (Missense)		HNSC_MUSE	TCGA-CV-5977-01A-11D-1683-08	TCGA-CV-5977-11A-01D-1683-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S214R	0.384	125.0	0.0	0.0																									ROS1 p.S214R (Missense)		HNSC_MUSE	TCGA-CN-A63U-01A-11D-A30E-08	TCGA-CN-A63U-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.M244I	0.1818	88.0	0.0	0.0																									AURKB p.M244I (Missense)		HNSC_MUSE	TCGA-CV-7102-01A-11D-2012-08	TCGA-CV-7102-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.3226	31.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-A45Z-01A-21D-A25D-08	TCGA-CV-A45Z-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.G35W	0.1932	88.0	0.0	0.0																									CDKN2A p.G35W (Missense)		HNSC_MUSE	TCGA-CV-A45Z-01A-21D-A25D-08	TCGA-CV-A45Z-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.7097	31.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CR-7380-01A-11D-2012-08	TCGA-CR-7380-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.T75M	0.3113	106.0	0.0	0.0																									RUNX1T1 p.T75M (Missense)		HNSC_MUSE	TCGA-CV-A45R-01A-11D-A24D-08	TCGA-CV-A45R-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	PMS2	Missense	p.I334M	0.5125	80.0	0.0	0.0																									PMS2 p.I334M (Missense)		HNSC_MUSE	TCGA-BB-4227-01A-01D-1870-08	TCGA-BB-4227-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.S1705L	0.4444	72.0	0.0	0.0																									ROS1 p.S1705L (Missense)		HNSC_MUSE	TCGA-CN-6997-01A-11D-2012-08	TCGA-CN-6997-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.R87P	0.6154	13.0	0.0	0.0																									CDKN2A p.R87P (Missense)		HNSC_MUSE	TCGA-CN-6997-01A-11D-2012-08	TCGA-CN-6997-10A-01D-2013-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.K867Q	0.2857	119.0	0.0	0.0																									EML4 p.K867Q (Missense)		HNSC_MUSE	TCGA-HD-8635-01A-11D-2394-08	TCGA-HD-8635-10A-01D-2394-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.V1489F	0.3443	61.0	0.0	0.0																									ROS1 p.V1489F (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R301H	0.1467	150.0	0.0	0.0																									RUNX1T1 p.R301H (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108V	0.8571	28.0	0.0	0.0																									CDKN2A p.D108V (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.A333V	0.625	88.0	0.0	0.0																									RB1 p.A333V (Missense)		HNSC_MUSE	TCGA-CR-7370-01A-11D-2129-08	TCGA-CR-7370-10A-01D-2129-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S146L	0.3182	44.0	0.0	0.0																									MYC p.S146L (Missense)		HNSC_MUSE	TCGA-D6-6825-01A-21D-1912-08	TCGA-D6-6825-10A-01D-1912-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E120*	0.413	46.0	0.0	0.0																									CDKN2A p.E120* (Nonsense)		HNSC_MUSE	TCGA-D6-6825-01A-21D-1912-08	TCGA-D6-6825-10A-01D-1912-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A6V	0.1746	63.0	0.0	0.0																									PDGFRB p.A6V (Missense)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.6364	22.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R410C	0.3208	53.0	0.0	0.0																									BRD4 p.R410C (Missense)		HNSC_MUSE	TCGA-CN-5370-01A-01D-2012-08	TCGA-CN-5370-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E88*	0.2041	49.0	0.0	0.0																									CDKN2A p.E88* (Nonsense)		HNSC_MUSE	TCGA-CQ-A4C6-01A-11D-A25D-08	TCGA-CQ-A4C6-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R58*	0.5833	12.0	0.0	0.0																									CDKN2A p.R58* (Nonsense)		HNSC_MUSE	TCGA-CV-6941-01A-11D-1912-08	TCGA-CV-6941-10A-01D-1912-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.A636V	0.175	40.0	0.0	0.0																									NTRK3 p.A636V (Missense)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.I145F	0.2963	54.0	0.0	0.0																									KEAP1 p.I145F (Missense)		HNSC_MUSE	TCGA-CV-5978-01A-11D-1683-08	TCGA-CV-5978-11A-01D-1683-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.H83R	0.3871	31.0	0.0	0.0																									CDKN2A p.H83R (Missense)		HNSC_MUSE	TCGA-BA-5557-01A-01D-1512-08	TCGA-BA-5557-10A-01D-1512-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.A140V	0.4059	101.0	0.0	0.0																									POT1 p.A140V (Missense)		HNSC_MUSE	TCGA-QK-A8ZA-01A-11D-A391-08	TCGA-QK-A8ZA-10A-01D-A394-08
Biologically Relevant				Somatic Variant	EWSR1	Missense	p.R607Q	0.2222	27.0	0.0	0.0																									EWSR1 p.R607Q (Missense)		HNSC_MUSE	TCGA-CV-A6K2-01A-11D-A31L-08	TCGA-CV-A6K2-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.4	35.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-7413-01A-11D-2078-08	TCGA-CV-7413-10A-01D-2078-08
Biologically Relevant				Somatic Variant	BRD4	Missense	p.R616Q	0.1985	131.0	0.0	0.0																									BRD4 p.R616Q (Missense)		HNSC_MUSE	TCGA-CV-7261-01A-11D-2012-08	TCGA-CV-7261-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.8824	51.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-6962-01A-11D-1912-08	TCGA-CV-6962-10A-01D-1912-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.4375	32.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-7101-01A-11D-2012-08	TCGA-CV-7101-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.Q50R	0.5455	209.0	0.0	0.0																									CDKN2A p.Q50R (Missense)		HNSC_MUSE	TCGA-BA-7269-01A-11D-2012-08	TCGA-BA-7269-10A-01D-2013-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.T598A	0.5248	101.0	0.0	0.0																									KEAP1 p.T598A (Missense)		HNSC_MUSE	TCGA-BA-7269-01A-11D-2012-08	TCGA-BA-7269-10A-01D-2013-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.H350Y	0.2128	47.0	0.0	0.0																									LIMK2 p.H350Y (Missense)		HNSC_MUSE	TCGA-T2-A6WX-01A-12D-A34J-08	TCGA-T2-A6WX-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.4839	62.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-CN-4731-01A-01D-1434-08	TCGA-CN-4731-10A-01D-1434-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.E1294K	0.3585	159.0	0.0	0.0																									COL1A1 p.E1294K (Missense)		HNSC_MUSE	TCGA-CN-4731-01A-01D-1434-08	TCGA-CN-4731-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.F90L	0.4667	45.0	0.0	0.0																									CDKN2A p.F90L (Missense)		HNSC_MUSE	TCGA-IQ-A6SH-01A-12D-A34J-08	TCGA-IQ-A6SH-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.P245A	0.1029	68.0	0.0	0.0																									RB1 p.P245A (Missense)		HNSC_MUSE	TCGA-F7-A50J-01A-21D-A28R-08	TCGA-F7-A50J-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	MLH1	Missense	p.V647L	0.1402	264.0	0.0	0.0																									MLH1 p.V647L (Missense)		HNSC_MUSE	TCGA-UF-A7JA-01A-12D-A34J-08	TCGA-UF-A7JA-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.F602L	0.5333	15.0	0.0	0.0																									MTOR p.F602L (Missense)		HNSC_MUSE	TCGA-CV-6933-01A-11D-1912-08	TCGA-CV-6933-10A-01D-1912-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.R326L	0.3594	64.0	0.0	0.0																									NTRK3 p.R326L (Missense)		HNSC_MUSE	TCGA-D6-6823-01A-11D-1912-08	TCGA-D6-6823-10A-01D-1912-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5085	59.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-MT-A67A-01A-11D-A30E-08	TCGA-MT-A67A-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.Q778E	0.1356	118.0	0.0	0.0																									EML4 p.Q778E (Missense)		HNSC_MUSE	TCGA-F7-A50G-01A-11D-A25Y-08	TCGA-F7-A50G-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E88*	0.56	25.0	0.0	0.0																									CDKN2A p.E88* (Nonsense)		HNSC_MUSE	TCGA-CN-6013-01A-11D-1683-08	TCGA-CN-6013-10A-01D-1683-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.Q531R	0.2066	121.0	0.0	0.0																									NTRK3 p.Q531R (Missense)		HNSC_MUSE	TCGA-CV-5970-01A-11D-1683-08	TCGA-CV-5970-10A-01D-1870-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.H309N	0.2364	165.0	0.0	0.0																									RUNX1T1 p.H309N (Missense)		HNSC_MUSE	TCGA-UF-A71D-01A-12D-A34J-08	TCGA-UF-A71D-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.P63A	0.2623	61.0	0.0	0.0																									TMPRSS2 p.P63A (Missense)		HNSC_MUSE	TCGA-UF-A71D-01A-12D-A34J-08	TCGA-UF-A71D-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	POT1	Missense	p.L292F	0.3878	49.0	0.0	0.0																									POT1 p.L292F (Missense)		HNSC_MUSE	TCGA-UF-A7JS-01A-11D-A34J-08	TCGA-UF-A7JS-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1786F	0.1636	55.0	0.0	0.0																									ROS1 p.L1786F (Missense)		HNSC_MUSE	TCGA-HD-A6HZ-01A-12D-A31L-08	TCGA-HD-A6HZ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.D83G	0.0891	101.0	0.0	0.0																									CCNE1 p.D83G (Missense)		HNSC_MUSE	TCGA-HD-A6HZ-01A-12D-A31L-08	TCGA-HD-A6HZ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	RUNX1T1	Nonsense	p.R533*	0.3951	81.0	0.0	0.0																									RUNX1T1 p.R533* (Nonsense)		HNSC_MUSE	TCGA-CR-7389-01A-11D-2012-08	TCGA-CR-7389-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.1458	48.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-BA-A6DD-01A-12D-A31L-08	TCGA-BA-A6DD-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4286	35.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-BA-5558-01A-01D-1512-08	TCGA-BA-5558-10A-01D-1512-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.A331T	0.3421	38.0	0.0	0.0																									COL1A1 p.A331T (Missense)		HNSC_MUSE	TCGA-CV-5435-01A-01D-1683-08	TCGA-CV-5435-10A-01D-1870-08
Biologically Relevant				Somatic Variant	COL1A1	Nonsense	p.E33*	0.3	30.0	0.0	0.0																									COL1A1 p.E33* (Nonsense)		HNSC_MUSE	TCGA-F7-A61V-01A-11D-A28R-08	TCGA-F7-A61V-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R348K	0.0649	185.0	0.0	0.0																									RUNX1T1 p.R348K (Missense)		HNSC_MUSE	TCGA-BA-A6D8-01A-31D-A31L-08	TCGA-BA-A6D8-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E10*	0.6522	46.0	0.0	0.0																									CDKN2A p.E10* (Nonsense)		HNSC_MUSE	TCGA-QK-A6IJ-01A-11D-A31L-08	TCGA-QK-A6IJ-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E120*	0.4098	61.0	0.0	0.0																									CDKN2A p.E120* (Nonsense)		HNSC_MUSE	TCGA-CN-4736-01A-01D-1434-08	TCGA-CN-4736-10A-01D-1434-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.T174N	0.1524	105.0	0.0	0.0																									FGFR2 p.T174N (Missense)		HNSC_MUSE	TCGA-CV-6954-01A-11D-1912-08	TCGA-CV-6954-10A-01D-1912-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R458C	0.5357	56.0	0.0	0.0																									RUNX1T1 p.R458C (Missense)		HNSC_MUSE	TCGA-MT-A51X-01A-11D-A25Y-08	TCGA-MT-A51X-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.V239M	0.5641	78.0	0.0	0.0																									KEAP1 p.V239M (Missense)		HNSC_MUSE	TCGA-P3-A6T0-01A-12D-A34J-08	TCGA-P3-A6T0-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4483	29.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-7090-01A-11D-2012-08	TCGA-CV-7090-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.Q274L	0.3053	95.0	0.0	0.0																									RUNX1T1 p.Q274L (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.C2134R	0.4909	55.0	0.0	0.0																									NF1 p.C2134R (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.G429S	0.2188	32.0	0.0	0.0																									KEAP1 p.G429S (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	KEAP1	Missense	p.R234W	0.2319	69.0	0.0	0.0																									KEAP1 p.R234W (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	TMPRSS2	Missense	p.V64I	0.4394	66.0	0.0	0.0																									TMPRSS2 p.V64I (Missense)		HNSC_MUSE	TCGA-KU-A66S-01A-21D-A30E-08	TCGA-KU-A66S-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.45	20.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CN-5373-01A-01D-1434-08	TCGA-CN-5373-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X51_splice	0.5625	16.0	0.0	0.0																									CDKN2A p.X51_splice (Splice Site)		HNSC_MUSE	TCGA-CN-6996-01A-11D-1912-08	TCGA-CN-6996-10A-01D-1912-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.V125M	0.5526	76.0	0.0	0.0																									PDGFRB p.V125M (Missense)		HNSC_MUSE	TCGA-CN-6998-01A-23D-2012-08	TCGA-CN-6998-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.6667	33.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CN-6998-01A-23D-2012-08	TCGA-CN-6998-10A-01D-2013-08
Biologically Relevant				Somatic Variant	PDGFRB	Missense	p.A1045D	0.5	52.0	0.0	0.0																									PDGFRB p.A1045D (Missense)		HNSC_MUSE	TCGA-CN-6021-01A-11D-1683-08	TCGA-CN-6021-10A-01D-1683-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.L1947V	0.3208	53.0	0.0	0.0																									ROS1 p.L1947V (Missense)		HNSC_MUSE	TCGA-CV-7235-01A-11D-2012-08	TCGA-CV-7235-10A-01D-2013-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E2308K	0.2159	88.0	0.0	0.0																									ROS1 p.E2308K (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D240N	0.1966	178.0	0.0	0.0																									ROS1 p.D240N (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.N42S	0.3147	143.0	0.0	0.0																									ESRP1 p.N42S (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4054	37.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.P127L	0.2	40.0	0.0	0.0																									FLI1 p.P127L (Missense)		HNSC_MUSE	TCGA-D6-6516-01A-11D-1870-08	TCGA-D6-6516-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.P48L	0.2675	243.0	0.0	0.0																									CDKN2A p.P48L (Missense)		HNSC_MUSE	TCGA-CV-7180-01A-11D-2012-08	TCGA-CV-7180-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CCND1	Missense	p.P287L	0.2558	43.0	0.0	0.0																									CCND1 p.P287L (Missense)		HNSC_MUSE	TCGA-BA-A6DJ-01A-11D-A30E-08	TCGA-BA-A6DJ-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R68W	0.3226	31.0	0.0	0.0																									FLI1 p.R68W (Missense)		HNSC_MUSE	TCGA-CR-7398-01A-11D-2012-08	TCGA-CR-7398-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.W78*	0.7848	79.0	0.0	0.0																									RB1 p.W78* (Nonsense)		HNSC_MUSE	TCGA-CR-7398-01A-11D-2012-08	TCGA-CR-7398-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.K485N	0.3871	124.0	0.0	0.0																									RUNX1T1 p.K485N (Missense)		HNSC_MUSE	TCGA-BA-4078-01A-01D-1434-08	TCGA-BA-4078-10A-01D-1434-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.S45P	0.2308	78.0	0.0	0.0																									AURKB p.S45P (Missense)		HNSC_MUSE	TCGA-CN-5363-01A-01D-1434-08	TCGA-CN-5363-10A-01D-1434-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.N1898S	0.125	56.0	0.0	0.0																									MTOR p.N1898S (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	CDKN2C	Missense	p.T69A	0.3125	80.0	0.0	0.0																									CDKN2C p.T69A (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	MLH1	Nonsense	p.E102*	0.5672	67.0	0.0	0.0																									MLH1 p.E102* (Nonsense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NTRK2	Missense	p.T777M	0.2838	74.0	0.0	0.0																									NTRK2 p.T777M (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.C362S	0.1667	156.0	0.0	0.0																									NTRK3 p.C362S (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.A330V	0.202	99.0	0.0	0.0																									NF1 p.A330V (Missense)		HNSC_MUSE	TCGA-F7-A624-01A-22D-A30E-08	TCGA-F7-A624-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Nonsense	p.E1905*	0.2852	277.0	0.0	0.0																									ROS1 p.E1905* (Nonsense)		HNSC_MUSE	TCGA-D6-A74Q-01A-11D-A34J-08	TCGA-D6-A74Q-10A-02D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108Y	0.5217	23.0	0.0	0.0																									CDKN2A p.D108Y (Missense)		HNSC_MUSE	TCGA-D6-A74Q-01A-11D-A34J-08	TCGA-D6-A74Q-10A-02D-A34M-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I490T	0.1935	93.0	0.0	0.0																									ROS1 p.I490T (Missense)		HNSC_MUSE	TCGA-UF-A71B-01A-12D-A34J-08	TCGA-UF-A71B-10B-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5862	29.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-RS-A6TO-01A-32D-A34J-08	TCGA-RS-A6TO-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G1133E	0.4375	32.0	0.0	0.0																									COL1A1 p.G1133E (Missense)		HNSC_MUSE	TCGA-CN-A63W-01A-11D-A30E-08	TCGA-CN-A63W-10A-01D-A30H-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.E599K	0.2623	122.0	0.0	0.0																									ROS1 p.E599K (Missense)		HNSC_MUSE	TCGA-CV-7252-01A-11D-2012-08	TCGA-CV-7252-10A-01D-2013-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.Q1173E	0.1972	71.0	0.0	0.0																									ROS1 p.Q1173E (Missense)		HNSC_MUSE	TCGA-CQ-A4CD-01A-21D-A25D-08	TCGA-CQ-A4CD-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E69*	0.4375	16.0	0.0	0.0																									CDKN2A p.E69* (Nonsense)		HNSC_MUSE	TCGA-CQ-A4CD-01A-21D-A25D-08	TCGA-CQ-A4CD-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	TPX2	Missense	p.R288L	0.3478	69.0	0.0	0.0																									TPX2 p.R288L (Missense)		HNSC_MUSE	TCGA-CQ-A4CD-01A-21D-A25D-08	TCGA-CQ-A4CD-10A-01D-A25E-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.G1524V	0.2985	67.0	0.0	0.0																									MTOR p.G1524V (Missense)		HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.E408K	0.1406	64.0	0.0	0.0																									ESRP1 p.E408K (Missense)		HNSC_MUSE	TCGA-CR-7388-01A-11D-2012-08	TCGA-CR-7388-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.3214	28.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-F7-A61S-01A-11D-A28R-08	TCGA-F7-A61S-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.S136C	0.1852	54.0	0.0	0.0																									EPCAM p.S136C (Missense)		HNSC_MUSE	TCGA-CV-6961-01A-21D-1912-08	TCGA-CV-6961-10A-01D-1912-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.V419I	0.3386	189.0	0.0	0.0																									RUNX1T1 p.V419I (Missense)		HNSC_MUSE	TCGA-P3-A6T2-01A-11D-A34J-08	TCGA-P3-A6T2-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	NF1	Missense	p.S1448R	0.2174	23.0	0.0	0.0																									NF1 p.S1448R (Missense)		HNSC_MUSE	TCGA-CN-6989-01A-11D-1912-08	TCGA-CN-6989-10A-01D-1912-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.W110*	0.8	35.0	0.0	0.0																									CDKN2A p.W110* (Nonsense)		HNSC_MUSE	TCGA-CV-7414-01A-11D-2078-08	TCGA-CV-7414-10A-01D-2078-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.S146L	0.35	60.0	0.0	0.0																									MYC p.S146L (Missense)		HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.4231	26.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-H7-8501-01A-11D-2394-08	TCGA-H7-8501-10A-01D-2394-08
Biologically Relevant				Somatic Variant	IL12RB1	Missense	p.Q330H	0.16	50.0	0.0	0.0																									IL12RB1 p.Q330H (Missense)		HNSC_MUSE	TCGA-CN-5360-01A-01D-1434-08	TCGA-CN-5360-10A-01D-1434-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1212S	0.4429	70.0	0.0	0.0																									ROS1 p.R1212S (Missense)		HNSC_MUSE	TCGA-CV-7245-01A-11D-2012-08	TCGA-CV-7245-10A-01D-2013-08
Biologically Relevant				Somatic Variant	IL12RB1	Splice Site	p.X397_splice	0.1429	280.0	0.0	0.0																									IL12RB1 p.X397_splice (Splice Site)		HNSC_MUSE	TCGA-CV-7245-01A-11D-2012-08	TCGA-CV-7245-10A-01D-2013-08
Biologically Relevant				Somatic Variant	EPCAM	Missense	p.P178Q	0.1646	79.0	0.0	0.0																									EPCAM p.P178Q (Missense)		HNSC_MUSE	TCGA-CV-6942-01A-21D-2012-08	TCGA-CV-6942-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.Y44C	0.195	241.0	0.0	0.0																									CDKN2A p.Y44C (Missense)		HNSC_MUSE	TCGA-CV-6942-01A-21D-2012-08	TCGA-CV-6942-10A-01D-2013-08
Biologically Relevant				Somatic Variant	RB1	Splice Site	p.X500_splice	0.2353	17.0	0.0	0.0																									RB1 p.X500_splice (Splice Site)		HNSC_MUSE	TCGA-CR-6487-01A-11D-1870-08	TCGA-CR-6487-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.R1324M	0.2778	108.0	0.0	0.0																									ROS1 p.R1324M (Missense)		HNSC_MUSE	TCGA-IQ-A6SG-01A-12D-A34J-08	TCGA-IQ-A6SG-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	RB1	Nonsense	p.G435*	0.5146	103.0	0.0	0.0																									RB1 p.G435* (Nonsense)		HNSC_MUSE	TCGA-IQ-A6SG-01A-12D-A34J-08	TCGA-IQ-A6SG-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.4	50.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-CR-7379-01A-11D-2012-08	TCGA-CR-7379-10A-01D-2013-08
Biologically Relevant				Somatic Variant	FLI1	Missense	p.R324W	0.3913	23.0	0.0	0.0																									FLI1 p.R324W (Missense)		HNSC_MUSE	TCGA-C9-A480-01A-12D-A24D-08	TCGA-C9-A480-10A-01D-A24F-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.E120*	0.2778	36.0	0.0	0.0																									CDKN2A p.E120* (Nonsense)		HNSC_MUSE	TCGA-CV-6436-01A-11D-1683-08	TCGA-CV-6436-11A-01D-1683-08
Biologically Relevant				Somatic Variant	RUNX1T1	Missense	p.R379W	0.3033	122.0	0.0	0.0																									RUNX1T1 p.R379W (Missense)		HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	FGFR2	Missense	p.S605L	0.2917	408.0	0.0	0.0																									FGFR2 p.S605L (Missense)		HNSC_MUSE	TCGA-CV-A6K1-01A-11D-A31L-08	TCGA-CV-A6K1-10A-01D-A31J-08
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.G815C	0.3673	98.0	0.0	0.0																									COL1A1 p.G815C (Missense)		HNSC_MUSE	TCGA-F7-A622-01A-11D-A28R-08	TCGA-F7-A622-10A-01D-A28U-08
Biologically Relevant				Somatic Variant	EML4	Missense	p.P900R	0.1954	174.0	0.0	0.0																									EML4 p.P900R (Missense)		HNSC_MUSE	TCGA-CN-5355-01A-01D-1434-08	TCGA-CN-5355-10A-01D-1434-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.H1307D	0.1646	79.0	0.0	0.0																									ROS1 p.H1307D (Missense)		HNSC_MUSE	TCGA-CQ-7069-01A-11D-2394-08	TCGA-CQ-7069-10A-01D-2394-08
Biologically Relevant				Somatic Variant	RB1	Missense	p.E554K	0.1905	42.0	0.0	0.0																									RB1 p.E554K (Missense)		HNSC_MUSE	TCGA-CQ-7069-01A-11D-2394-08	TCGA-CQ-7069-10A-01D-2394-08
Biologically Relevant				Somatic Variant	CDKN2A	Nonsense	p.R80*	0.5	34.0	0.0	0.0																									CDKN2A p.R80* (Nonsense)		HNSC_MUSE	TCGA-CV-6959-01A-11D-1912-08	TCGA-CV-6959-10A-01D-1912-08
Biologically Relevant				Somatic Variant	MTOR	Missense	p.E709G	0.2545	55.0	0.0	0.0																									MTOR p.E709G (Missense)		HNSC_MUSE	TCGA-CV-5966-01A-11D-1683-08	TCGA-CV-5966-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.I903S	0.1286	140.0	0.0	0.0																									ROS1 p.I903S (Missense)		HNSC_MUSE	TCGA-CV-5966-01A-11D-1683-08	TCGA-CV-5966-10A-01D-1870-08
Biologically Relevant				Somatic Variant	EPCAM	Nonsense	p.Q5*	0.6111	18.0	0.0	0.0																									EPCAM p.Q5* (Nonsense)		HNSC_MUSE	TCGA-CR-6472-01A-11D-1870-08	TCGA-CR-6472-10A-01D-1870-08
Biologically Relevant				Somatic Variant	RAF1	Splice Site	p.X69_splice	0.3333	87.0	0.0	0.0																									RAF1 p.X69_splice (Splice Site)		HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.K367N	0.2206	136.0	0.0	0.0																									NTRK3 p.K367N (Missense)		HNSC_MUSE	TCGA-CV-A461-01A-41D-A25Y-08	TCGA-CV-A461-10A-01D-A25Y-08
Biologically Relevant				Somatic Variant	NTRK3	Missense	p.C231F	0.3824	34.0	0.0	0.0																									NTRK3 p.C231F (Missense)		HNSC_MUSE	TCGA-P3-A6SX-01A-11D-A34J-08	TCGA-P3-A6SX-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.D45N	0.1889	90.0	0.0	0.0																									LIMK2 p.D45N (Missense)		HNSC_MUSE	TCGA-CR-5248-01A-01D-2012-08	TCGA-CR-5248-10A-01D-2013-08
Biologically Relevant				Somatic Variant	LIMK2	Missense	p.E70K	0.2237	76.0	0.0	0.0																									LIMK2 p.E70K (Missense)		HNSC_MUSE	TCGA-CR-5248-01A-01D-2012-08	TCGA-CR-5248-10A-01D-2013-08
Biologically Relevant				Somatic Variant	TACC3	Missense	p.K748R	0.6316	76.0	0.0	0.0																									TACC3 p.K748R (Missense)		HNSC_MUSE	TCGA-CV-7263-01A-11D-2012-08	TCGA-CV-7263-10A-01D-2013-08
Biologically Relevant				Somatic Variant	CDKN2A	Missense	p.D108Y	0.4545	44.0	0.0	0.0																									CDKN2A p.D108Y (Missense)		HNSC_MUSE	TCGA-CN-A6V3-01A-12D-A34J-08	TCGA-CN-A6V3-10A-01D-A34M-08
Biologically Relevant				Somatic Variant	MYC	Missense	p.Q380H	0.2431	469.0	0.0	0.0																									MYC p.Q380H (Missense)		HNSC_MUSE	TCGA-BA-4076-01A-01D-1434-08	TCGA-BA-4076-10A-01D-1434-08
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.D261G	0.4632	231.0	0.0	0.0																									CCNE1 p.D261G (Missense)		HNSC_MUSE	TCGA-BA-4076-01A-01D-1434-08	TCGA-BA-4076-10A-01D-1434-08
Biologically Relevant				Somatic Variant	AURKB	Missense	p.R95W	0.2745	51.0	0.0	0.0																									AURKB p.R95W (Missense)		HNSC_MUSE	TCGA-DQ-5631-01A-01D-1870-08	TCGA-DQ-5631-10A-01D-1870-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.C1122F	0.325	40.0	0.0	0.0																									ROS1 p.C1122F (Missense)		HNSC_MUSE	TCGA-CV-6935-01A-11D-1912-08	TCGA-CV-6935-10A-01D-1912-08
Biologically Relevant				Somatic Variant	ROS1	Missense	p.A651V	0.4091	132.0	0.0	0.0																									ROS1 p.A651V (Missense)		HNSC_MUSE	TCGA-CV-6935-01A-11D-1912-08	TCGA-CV-6935-10A-01D-1912-08
Biologically Relevant				Somatic Variant	MDM2	Missense	p.S259Y	0.4091	66.0	0.0	0.0																									MDM2 p.S259Y (Missense)		HNSC_MUSE	TCGA-T3-A92M-01A-31D-A391-08	TCGA-T3-A92M-10A-01D-A394-08
Biologically Relevant				Somatic Variant	ESRP1	Missense	p.P562S	0.224	125.0	0.0	0.0																									ESRP1 p.P562S (Missense)		HNSC_MUSE	TCGA-BA-5152-01A-02D-1870-08	TCGA-BA-5152-10A-01D-1870-08
Biologically Relevant				Somatic Variant	CDKN2A	Splice Site	p.X153_splice	0.4714	70.0	0.0	0.0																									CDKN2A p.X153_splice (Splice Site)		HNSC_MUSE	TCGA-BA-5152-01A-02D-1870-08	TCGA-BA-5152-10A-01D-1870-08
Biologically Relevant				Somatic Variant	FGFR1	Missense	p.R209H	0.2419	215.0	0.0	0.0																									FGFR1 p.R209H (Missense)		HNSC_MUSE	TCGA-CQ-6223-01A-11D-1912-08	TCGA-CQ-6223-10A-01D-1912-08
Biologically Relevant				Somatic Variant	NF1	Nonsense	p.Q400*	0.4296	135.0	0.0	0.0																									NF1 p.Q400* (Nonsense)		HNSC_MUSE	TCGA-MT-A7BN-01A-12D-A34J-08	TCGA-MT-A7BN-10A-01D-A34M-08
Biologically Relevant				Microsatellite Stability	Supporting variants		POLE p.X21_splice (Splice Site), PMS2 p.R3* (Nonsense), PMS2 p.X55_splice (Splice Site), JAK1 p.X1124_splice (Splice Site), PRDM2 p.Q1435* (Nonsense), MSH3 p.S206* (Nonsense), MSH3 p.X1044_splice (Splice Site), DOCK3 p.E337* (Nonsense), JAK1 p.W1047* (Nonsense), MLH1 p.E102* (Nonsense), POLE p.E1376* (Nonsense), POLE p.X823_splice (Splice Site)																													Supporting variants: POLE p.X21_splice (Splice Site), PMS2 p.R3* (Nonsense), PMS2 p.X55_splice (Splice Site), JAK1 p.X1124_splice (Splice Site), PRDM2 p.Q1435* (Nonsense), MSH3 p.S206* (Nonsense), MSH3 p.X1044_splice (Splice Site), DOCK3 p.E337* (Nonsense), JAK1 p.W1047* (Nonsense), MLH1 p.E102* (Nonsense), POLE p.E1376* (Nonsense), POLE p.X823_splice (Splice Site)		HNSC_MUSE		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.542																													COSMIC Signature (version 2) 1 (54%)		HNSC_MUSE		
